Practical Strategies and Concepts in GPCR Allosteric Modulator Discovery: Recent Advances with Metabotropic Glutamate Receptors

Chemical Reviews

Volumn 116, Issue 11, 2016, Pages 6707-6741

  Lindsley, Craig W ^a   Emmitte, Kyle A ^b   Hopkins, Corey R ^a   Bridges, Thomas M ^a   Gregory, Karen J ^d   Niswender, Colleen M ^a,c   Conn, P Jeffrey ^a,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

MODULATORS;

ALLOSTERIC MODULATION; ALLOSTERIC MODULATORS; DRUG METABOLISMS; HETERODIMERS; MEDICINAL CHEMISTRY; METABOTROPIC GLUTAMATE RECEPTORS; MOLECULAR SWITCHES; PRACTICAL SOLUTIONS;

LIGANDS;

G PROTEIN COUPLED RECEPTOR; LIGAND; METABOTROPIC RECEPTOR;

ALLOSTERISM; CHEMISTRY; DRUG DESIGN; GENETICS; HUMAN; KINETICS; METABOLISM; STRUCTURE ACTIVITY RELATION;

ALLOSTERIC REGULATION; DRUG DESIGN; HUMANS; KINETICS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84974602761     PISSN: 00092665     EISSN: 15206890     Source Type: Journal    
DOI: 10.1021/acs.chemrev.5b00656     Document Type: Review

References (345)

1. Kenakin, T.; Miller, L. J. Seven Transmembrane Receptors as Shapeshifting Proteins: The Impact of Allosteric Modulation and Functional Selectivity on New Drug Discovery Pharmacol. Rev. 2010, 62, 265-304 10.1124/pr.108.000992
2. Christopoulos, A. 2002. Allosteric Binding Sites on Cell Surface Receptors: Novel Targets for Drug Discovery Nat. Rev. Drug Discovery 2002, 1, 198-210 10.1038/nrd746
3. Kenakin, T. P. 7TM Receptor Allostery: Putting Numbers to Shapeshifting Proteins Trends Pharmacol. Sci. 2009, 30, 460-469 10.1016/j.tips.2009.06.007
4. Lane, R. J.; Abdul-Ridha, A.; Canals, M. 2013. Regulation of G Protein-Coupled Receptors by Allosteric Ligands ACS Chem. Neurosci. 2013, 4, 527-534 10.1021/cn400005t
5. Fenton, A. W. Allostery: An Illustrated Definition for the Second Secret of Life Trends Biochem. Sci. 2008, 33, 420-425 10.1016/j.tibs.2008.05.009
6. Conn, P. J.; Christopoulos, A.; Lindsley, C. W. Allosteric Modulators of GPCRs as a Novel Approach to Treatment of CNS Disorders Nat. Rev. Drug Discovery 2009, 8, 41-54 10.1038/nrd2760
7. Bridges, T. M.; Lindsley, C. W. G-Protein Coupled Receptors: From Classical Modes of Modulation to Allosteric Mechanisms ACS Chem. Biol. 2008, 3, 530-542 10.1021/cb800116f
8. Christopoulos, A.; Kenakin, T. G Protein-Coupled Receptors Allosterism and Complexing Pharmacol. Rev. 2002, 54, 323-374 10.1124/pr.54.2.323
9. Lindsley, C. W. 2013 Philip S. Portoghese Medicinal Chemistry Lectureship: Drug Discovery Targeting Allosteric Sites J. Med. Chem. 2014, 57, 7485-7498 10.1021/jm5011786
10. Conn, P. J.; Lindsley, C. W.; Meiler, J.; Niswender, C. M. Opportunities and Challenges in the Discovery of Allosteric Modulators of GPCRs for the Treatment of CNS Disorders Nat. Rev. Drug Discovery 2014, 13, 692-708 10.1038/nrd4308
11. Wenthur, C. J.; Gentry, P. R.; Mathews, T. P.; Lindsley, C. W. Drugs for Allosteric Sites on Receptors Annu. Rev. Pharmacol. Toxicol. 2014, 54, 165-184 10.1146/annurev-pharmtox-010611-134525
12. Menniti, F. S.; Lindsley, C. W.; Conn, P. J.; Pandit, J.; Zagouras, P.; Volkmann, R. A. Allosteric Modulation for the Treatment of Schizophrenia: Targeting Glutamatergic Networks Curr. Top. Med. Chem. 2013, 13, 26-54 10.2174/1568026611313010005
13. Monod, J.; Wyman, J.; Changeux, J.-P. On the Nature of Allosteric Transitions: A Plausible Model J. Mol. Biol. 1965, 12, 88-118 10.1016/S0022-2836(65)80285-6
14. Möhler, H.; Fritschy, J. M.; Rudolph, U. A New Benzodiazepine Pharmacology J. Pharmacol. Exp. Ther. 2002, 300, 2-8 10.1124/jpet.300.1.2
15. Lagerström, M. C.; Schiöth, H. B. Structural Diversity of G Protein-Coupled Receptors and Significance for Drug Discovery Nat. Rev. Drug Discovery 2008, 7, 339-357 10.1038/nrd2518
16. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. How Many Drug Targets are There? Nat. Rev. Drug Discovery 2006, 5, 993-996 10.1038/nrd2199
17. Lindsley, C. W. 2014 Prescription Medications in the United States: Tremendous Growth, Speciality/Orphan Drug Expansion and CNS Dispensed Prescriptions Continue to Increase ACS Chem. Neurosci. 2015, 6, 811-812 10.1021/acschemneuro.5b00148
18. Jacobson, K. A. New Paradigms in GPCR Drug Discovery Biochem. Pharmacol. 2015, 98, 541-555 10.1016/j.bcp.2015.08.085
19. Urban, D. J.; Roth, B. L. DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility Annu. Rev. Pharmacol. Toxicol. 2015, 55, 399-417 10.1146/annurev-pharmtox-010814-124803
20. Chen, X.; Choo, H.; Huang, X.-P.; Yang, X.; Stone, O.; Roth, B. L.; Jin, J. The First Structure-Activity Relationship Studies for Designer Drugs ACS Chem. Neurosci. 2015, 6, 476-484 10.1021/cn500325v
21. Harrington, P. E.; Fotsch, C. Calcium Sensing Receptor Activators: Calcimimetics Curr. Med. Chem. 2007, 14, 3027-3034 10.2174/092986707782794096
22. Dorr, P.; Westby, M.; Dobbs, S.; Griffin, P.; Irvine, B.; Macartney, M.; Mori, J.; Rickett, G.; Smith-Burchnell, C.; Napier, C.; Webster, R.; Armour, D.; Price, D.; Stammen, B.; Wood, A.; Perros, M. Maraviroc (UK-427,857), a Potent, Orally Bioavailable, and Selective Small-Molecule Inhibitor of Chemokine Receptor CCR5 with Broad-Spectrum Anti-Human Immunodeficiency Virus Type 1 Activity Antimicrob. Agents Chemother. 2005, 49, 4721-4732 10.1128/AAC.49.11.4721-4732.2005
23. Emmitte, K. A. mGlu5 Negative Allosteric Modulators: A Patent Review (2010-2012) Expert Opin. Ther. Pat. 2013, 23, 393-408 10.1517/13543776.2013.760544
24. Rocher, J.-P.; Bonnet, B.; Boléa, C.; Lütjens, R.; Le Poul, E.; Poli, S.; Epping-Jordan, M.; Bessis, A.-S.; Ludwig, B.; Mutel, V. mGluR5 Negative Allosteric Modulators Overview: A Medicinal Chemistry Approach Towards a Series of Novel Therapeutic Agents Curr. Top. Med. Chem. 2011, 11, 680-695 10.2174/1568026611109060680
25. [3H]-JNJ-40068782 J. Pharmacol. Exp. Ther. 2013, 346, 514-527 10.1124/jpet.113.204990
26. 2 Positive Allosteric Modulators for the Treatment of Schizophrenia? ACS Chem. Neurosci. 2013, 4, 211-213 10.1021/cn400023y
27. Rodriguez, A. L.; Nong, Y.; Sekaran, N. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A Close Structural Analog of 2-Methyl-6-(phenylethynyl)-pyridine Acts as a Neutral Allosteric Site Ligand on Metabotropic Glutamate Receptor Subtype 5 and Blocks the Effects of Multiple Allosteric Modulators Mol. Pharmacol. 2005, 68, 1793-1802 10.1124/mol.105.016139
28. 5 Negative Allosteric Modulators Attenuate Cocaine Self-Administration, Demonstrate Antidepressant- and Anxiolytic-Like Activity and Lack Psychotomimetic Effects Neuropsychopharmacology 2015, 10.1038/npp.2015.265
29. Nickols, H. H.; Yuh, J. P.; Gregory, K.; Morrison, R.; Bates, B. S.; Stauffer, S.; Emmitte, K.; Bubser, M.; Peng, W.; Nedelcovych, M. T. et al. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with High in Vivo Efficacy J. Pharmacol. Exp. Ther. 2016, 356, 123-136 10.1124/jpet.115.226597
30. 1 Muscarinic Acetylcholine Receptor Induce Brain Region-Specific Responses and Correspond with Behavioral Effects in Animal Models J. Neurosci. 2012, 32, 8532-8544 10.1523/JNEUROSCI.0337-12.2012
31. 1 Allosteric Agonism and Result in Pan-mAChR Orthosteric Antagonism Bioorg. Med. Chem. Lett. 2013, 23, 223-227 10.1016/j.bmcl.2012.10.132
32. 1 Agonist VU0364572 Reveals Molecular Switches in Pharmacology as Well as a Bitopic Binding Mode ACS Chem. Neurosci. 2012, 3, 1025-1036 10.1021/cn300103e
33. Sharma, S.; Rodriguez, A.; Conn, P. J.; Lindsley, C. W. Synthesis and SAR of a mGluR5 Allosteric Partial Antagonist Lead: Unexpected Modulation of Pharmacology with Slight Structural Modifications to a 5-(Phenylethynyl)pyrimidine Scaffold Bioorg. Med. Chem. Lett. 2008, 18, 4098-4101 10.1016/j.bmcl.2008.05.091
34. Sharma, S.; Kedrowski, J.; Rook, J. M.; Smith, J. M.; Jones, C. K.; Rodriguez, A. L.; Conn, P. J.; Lindsley, C. W. Discovery of Molecular Switches that Modulate Modes of mGluR5 Pharmacology in Vitro and in Vivo Within a Series of Functionalized 5-(Phenylethynyl)pyrimidines J. Med. Chem. 2009, 52, 4103-4106 10.1021/jm900654c
35. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. 'Molecular Switches' on Allosteric Ligands that Modulate Modes of Pharmacology Biochemistry 2011, 50, 2403-2410 10.1021/bi200129s
36. Rodriguez, A. L.; Grier, M. D.; Jones, C. K.; Herman, E. J.; Kane, A. S.; Smith, R. L.; Williams, R.; Zhou, Y.; Marlo, J. E.; Days, E. L. et al. Discovery of Novel Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Reveals Chemical and Functional Diversity and in Vivo Activity in Rat Behavioral Models of Anxiolytic and Antipsychotic Activity Mol. Pharm. 2010, 78, 1105-1123 10.1124/mol.110.067207
37. Bridges, T. M.; Rook, J. M.; Noetzel, M. J.; Morrison, R. D.; Zhou, Y.; Gogliotti, R. D.; Vinson, P. N.; Jones, C. K.; Niswender, C. M.; Lindsley, C. W. et al. Biotransformation of a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 5 Contributes to Seizures in Rats Involving a Receptor Agonism-Dependent Mechanism Drug Metab. Dispos. 2013, 41, 1703-1714 10.1124/dmd.113.052084
38. Bertrand, D.; Gopalakrishnan, M. Allosteric Modulation of Nicotinic Acetylcholine Receptors Biochem. Pharmacol. 2007, 74, 1155-1163 10.1016/j.bcp.2007.07.011
39. Cho, H. P.; Engers, D. W.; Venable, D. F.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J.; Emmitte, K. A.; Rodriguez, A. L. A Novel Class of Succinimide-Derived Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Provides Insight into a Disconnect in Activity Between Rat and Human Receptors ACS Chem. Neurosci. 2014, 5, 597-610 10.1021/cn5000343
40. Rajagopal, S.; Ahn, S.; Rominger, D. H.; Gowen-MacDonald, W.; Lam, C. M.; DeWire, S. M.; Violin, J. D.; Lefkowitz, R. J. Quantifying Ligand Bias at Seven-Transmembrane receptors Mol. Pharmacol. 2011, 80, 367-377 10.1124/mol.111.072801
41. Kenakin, T.; Watson, C.; Muniz-Medina, V.; Christopoulos, A.; Novick, S. A Simple Method for Quantifying Functional Selectivity and Agonist Bias ACS Chem. Neurosci. 2012, 3, 193-203 10.1021/cn200111m
42. Kenakin, T. Biased Signalling and Allosteric Machines: New Vistas and Challenges for Drug Discovery Br. J. Pharmacol. 2012, 165, 1659-1669 10.1111/j.1476-5381.2011.01749.x
43. Kenakin, T.; Christopoulos, A. Signalling Bias in New Drug Discovery: Detection, Quantification and Therapeutic Impact Nat. Rev. Drug Discovery 2013, 12, 205-216 10.1038/nrd3954
44. Leach, K.; Loiacono, E. I.; Felder, C. C.; McKinzie, D. L.; Mogg, A.; Shaw, D. B.; Sexton, P. M.; Christopoulos, A. Molecular Mechanisms of Action and in Vivo Validation of an M4Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties Neuropsychopharmacology 2010, 35, 855-869 10.1038/npp.2009.194
45. Zhang, Y.; Rodriguez, A. L.; Conn, P. J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes J. Pharmacol. Exp. Ther. 2005, 315, 1212-1219 10.1124/jpet.105.090308
46. Sheffler, D. J.; Conn, P. J. Allosteric Potentiators of Metabotropic Glutamate Receptor Subtype 1a Differentially Modulate Independent Signaling Pathways in Baby Hamster Kidney Cells Neuropharmacology 2008, 55, 419-427 10.1016/j.neuropharm.2008.06.047
47. Leach, K.; Wen, A.; Davey, A. E.; Sexton, P. M.; Conigrave, A. D.; Christopoulos, A. Identification of Molecular Phenotypes and Biased Signaling Induced by Naturally Occurring Mutations of the Human Calcium-Sensing Receptor Endocrinology 2012, 153, 4304-4316 10.1210/en.2012-1449
48. Davey, A. E.; Leach, K.; Valant, C.; Conigrave, A. D.; Sexton, P. M.; Christopoulos, A. Positive and Negative Allosteric Modulators Promote Biased Signaling at the Calcium-Sensing Receptor Endocrinology 2012, 153, 1232-1241 10.1210/en.2011-1426
49. Ahn, K. H.; Mahmoud, M. M.; Kendall, D. A. Allosteric Modulator ORG27569 Induces CB1 Cannabinoid Receptor High Affinity Agonist Binding State, Receptor Internalization, and Gi Protein-Independent ERK1/2 Kinase Activation J. Biol. Chem. 2012, 287, 12070-12082 10.1074/jbc.M111.316463
50. Niswender, C. M.; Johnson, K. A.; Miller, N. R.; Ayala, J. E.; Luo, Q.; Williams, R.; Saleh, S.; Orton, D.; Weaver, C. D.; Conn, P. J. Context-Dependent Pharmacology Exhibited by Negative Allosteric Modulators of Metabotropic Glutamate Receptor 7 Mol. Pharmacol. 2010, 77, 459-468 10.1124/mol.109.058768
51. 1 Muscarinic Receptors Reveals Multiple Modes of Activity Mol. Pharm. 2009, 75 (3) 577-588 10.1124/mol.108.052886
52. 5 Signaling Mol. Pharmacol. 2013, 83, 835-847 10.1124/mol.112.082891
53. 5 Determine Differences in in Vivo Activity Biol. Psychiatry 2013, 73, 501-509 10.1016/j.biopsych.2012.09.012
54. 5 Modulation of NMDAR Currents Neuron 2015, 86, 1029-1040 10.1016/j.neuron.2015.03.063
55. 5 Positive Allosteric Modulator Clinical Candidate Targeting Schizophrenia ACS Med. Chem. Lett. 2015, 6, 716-720 10.1021/acsmedchemlett.5b00181
56. van der Westhuizen, E. T.; Valant, C.; Sexton, P. M.; Christopoulos, A. Endogenous Allosteric Modulators of G Protein-Coupled Receptors J. Pharmacol. Exp. Ther. 2015, 353, 246-260 10.1124/jpet.114.221606
57. Christopoulos, A.; Changeux, J. P.; Catterall, W. A.; Fabbro, D.; Burris, T. P.; Cidlowski, J. A.; Olsen, R. W.; Peters, J. A.; Neubig, R. R.; Pin, J. P. et al. International Union of Basic and Clinical Pharmacology. XC. Multisite Pharmacology: Recommendations for the Nomenclature of Receptor Allosterism and Allosteric Ligands Pharmacol. Rev. 2014, 66, 918-947 10.1124/pr.114.008862
58. Hemstapat, K.; Da Costa, H.; Nong, Y.; Brady, A. E.; Luo, Q.; Niswender, C. M.; Tamagnan, G. D.; Conn, P. J. A Novel Family of Potent Negative Allosteric Modulators of Group II Metabotropic Glutamate Receptors J. Pharmacol. Exp. Ther. 2007, 322, 254-264 10.1124/jpet.106.117093
59. 1 Receptor Antagonist Neuropharmacology 2004, 47, 961-972 10.1016/j.neuropharm.2004.08.007
60. Litschig, S.; Gasparini, F.; Rueegg, D.; Stoehr, N.; Flor, P. J.; Vranesic, I.; Prezeau, L.; Pin, J.-P.; Thomsen, C.; Kuhn, R. CPCCOET, a Noncompetitive Metabotropic Glutamate Receptor 1 Antagonist, Inhibits Receptor Signalling Without Affecting Glutamate Binding Mol. Pharmacol. 1999, 55, 453-461
61. Lundstrom, L.; Bissantz, C.; Beck, J.; Wettstein, J. G.; Woltering, T. J.; Wichmann, J.; Gatti, S. Structural Determinants of Allosteric Antagonism at Metabotropic Glutamate Receptor 2: Mechanistic Studies with New Potent Negative Allosteric Modulators Br. J. Pharmacol. 2011, 164, 521-527 10.1111/j.1476-5381.2011.01409.x
62. O'Brien, J. A.; Lemaire, W.; Chen, T.-B.; Chang, R. S. L.; Jacobson, M. A.; Ha, S. N.; Lindsley, C. W.; Schaffhauser, H. J.; Sur, C.; Pettibone, D. J.; Conn, P. J.; Williams, D. L., Jr. A Family of Highly Selective Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGluR5) Mol. Pharmacol. 2003, 64, 731-741 10.1124/mol.64.3.731
63. 13501 Mol. Pharmacol. 2001, 60, 963-971 10.1124/mol.60.5.963
64. 5 Allosteric Modulator Cooperativity, Affintiy and Agonism: Enriching Structure-Function Studies and Structure-Activity Relationships Mol. Pharmacol. 2012, 82, 860-875 10.1124/mol.112.080531
65. Parmentier-Batteur, S.; Hutson, P. H.; Menzel, K.; Uslaner, J. M.; Mattson, B. A.; O'Brien, J. A.; Magliaro, B. C.; Forest, T.; Stump, C. A.; Tynebor, R. M. et al. Mechanism Based Neurotoxicity of mGlu5 Positive Allosteric Modulators - Development Challenges for a Promising Novel Antipsychotic Target Neuropharmacology 2014, 82, 161-173 10.1016/j.neuropharm.2012.12.003
66. Ahn, S.; Shenoy, S. K.; Wei, H.; Lefkowitz, R. J. Differential Kinetic and Spatial Patterns of β-Arrestin and G Protein-mediated ERK Activation by the Angiotensin II Receptor J. Biol. Chem. 2004, 279, 35518-35525 10.1074/jbc.M405878200
67. Dias, J. A.; Bonnet, B.; Weaver, B. A.; Watts, J.; Kluetzman, K.; Thomas, R. M.; Poli, S.; Mutel, V.; Campo, B. A Negative Allosteric Modulator Demonstrates Biased Antagonism of the Follicle Stimulating Hormone Receptor Mol. Cell. Endocrinol. 2011, 333, 143-150 10.1016/j.mce.2010.12.023
68. Jalan-Sakrikar, N.; Field, J. R.; Klar, R.; Mattmann, M. E.; Gregory, K. J.; Zamorano, R.; Engers, D. W.; Bollinger, S. R.; Weaver, C. D.; Days, E. L. et al. Identification of Positive Allosteric Modulators VU0155904 (ML397) and VU0422288 (ML396) Reveals New Insights Into the Biology of Metabotropic Glutamate Receptor 7 ACS Chem. Neurosci. 2014, 5, 1221-1237 10.1021/cn500153z
69. 1 Receptor Mol. Pharmacol. 2005, 68, 1484-1495 10.1124/mol.105.016162
70. Ehlert, F. J. Analysis of Allosterism in Functional Assays J. Pharmacol. Exp. Ther. 2005, 315, 740-754 10.1124/jpet.105.090886
71. Hall, D. A. Modeling the Functional Effects of Allosteric Modulators at Pharmacological Receptors: An Extension of the Two-State Model of Receptor Activation Mol. Pharmacol. 2000, 58, 1412-1423
72. May, L. T.; Avlani, V. A.; Sexton, P. M.; Christopoulos, A. Allosteric Modulation of G Protein-Coupled Receptors Curr. Pharm. Des. 2004, 10, 2003-2013 10.2174/1381612043384303
73. 3 Muscarinic Receptor by Amiodarone and N-ethylamiodarone: Application of the Four-Ligand Allosteric Two-state model Mol. Pharmacol. 2011, 80, 378-388 10.1124/mol.111.072991
74. Ehlert, F. J.; Griffin, M. T. Estimation of Ligand Affinity Constants for Receptor States in Functional Studies Involving the Allosteric Modulation of G Protein-Coupled Receptors: Implications for Ligand Bias J. Pharmacol. Toxicol. Methods 2014, 69, 253-279 10.1016/j.vascn.2014.01.002
75. Roche, D.; Gil, D.; Giraldo, J. Mechanistic Analysis of the Function of Agonists and Allosteric Modulators: Reconciling Two-State and Operational Models Br. J. Pharmacol. 2013, 169, 1189-1202 10.1111/bph.12231
76. Black, J. W.; Leff, P. Operational Models of Pharmacological Agonism Proc. R. Soc. London, Ser. B 1983, 220, 141-162 10.1098/rspb.1983.0093
77. Leach, K.; Sexton, P. M.; Christopoulos, A. Allosteric GPCR Modulators: Taking Advantage of Permissive Receptor Pharmacology Trends Pharmacol. Sci. 2007, 28, 382-389 10.1016/j.tips.2007.06.004
78. Valant, C.; Felder, C. C.; Sexton, P. M.; Christopoulos, A. Probe Dependence in the Allosteric Modulation of a G Protein-Coupled Receptor: Implications for Detection and Validation of Allosteric Ligand Effects Mol. Pharmacol. 2012, 81, 41-52 10.1124/mol.111.074872
79. Bernat, V.; Brox, R.; Heinrich, M. R.; Auberson, Y. P.; Tschammer, N. Ligand-Biased and Probe-Dependent Modulation of Chemokine Receptor CXCR3 Signaling by Negative Allosteric Modulators ChemMedChem 2015, 10, 566-574 10.1002/cmdc.201402507
80. Cook, A. E.; Mistry, S. N.; Gregory, K. J.; Furness, S. G.; Sexton, P. M.; Scammells, P. J.; Conigrave, A. D.; Christopoulos, A.; Leach, K. Biased Allosteric Modulation at the CaS Receptor Engendered by Structurally Diverse Calcimimetics Br. J. Pharmacol. 2015, 172, 185-200 10.1111/bph.12937
81. Wootten, D.; Savage, E. E.; Willard, F. S.; Bueno, A. B.; Sloop, K. W.; Christopoulos, A.; Sexton, P. M. Differential Activation and Modulation of the Glucagon-Like Peptide-1 Receptor by Small Molecule Ligands Mol. Pharmacol. 2013, 83, 822-834 10.1124/mol.112.084525
82. 1 Muscarinic Acetylcholine Receptor J. Biol. Chem. 2014, 289, 33701-33711 10.1074/jbc.M114.604967
83. 1 Muscarinic Acetylcholine Receptor J. Biol. Chem. 2014, 289, 6067-6079 10.1074/jbc.M113.539080
84. 4 Receptor as an Approach to Treating Schizophrenia Proc. Natl. Acad. Sci. U. S. A. 2008, 105, 10978-10983 10.1073/pnas.0800567105
85. Farrell, M.; Roth, B. L. Allosteric Antipsychotics: M4Muscarinic Potentiators as Novel Treatments for Schizophrenia Neuropsychopharmacology 2010, 35, 851-852 10.1038/npp.2009.206
86. Willard, F. S.; Wootten, D.; Showalter, A. D.; Savage, E. E.; Ficorilli, J.; Farb, T. B.; Bokvist, K.; Alsina-Fernandez, J.; Furness, S. G.; Christopoulos, A. et al. Small Molecule Allosteric Modulation of the Glucagon-Like Peptide-1 Receptor Enhances the Insulinotropic Effect of Oxyntomodulin Mol. Pharmacol. 2012, 82, 1066-1073 10.1124/mol.112.080432
87. Wootten, D.; Savage, E. E.; Valant, C.; May, L. T.; Sloop, K. W.; Ficorilli, J.; Showalter, A. D.; Willard, F. S.; Christopoulos, A.; Sexton, P. M. Allosteric Modulation of Endogenous Metabolites as an Avenue for Drug Discovery Mol. Pharmacol. 2012, 82, 281-290 10.1124/mol.112.079319
88. Morris, L. C.; Days, E. L.; Turney, M.; Mi, D.; Lindsley, C. W.; Weaver, C. D.; Niswender, K. D. A Duplexed High-Throughput Screen to Identify Allosteric Modulators of the Glucagon-Like Peptide 1 and Glucagon Receptor J. Biomol. Screening 2014, 19, 847-858 10.1177/1087057114520971
89. Morris, L. C.; Nance, K. D.; Gentry, P. R.; Days, E. L.; Weaver, C. D.; Niswender, C. M.; Thompson, A. D.; Jones, C. K.; Locuson, C. W.; Morrison, R. D. et al. Discovery of (S)-2-Cyclopentyl-N-((1-isopropylpyrrolidin2-yl)-9-methyl-1-oxo-2,9-dihydro-1H-pyrrido[3,4-b]indole-4-carboxamide (VU0453379): A Novel, CNS Penetrant GLP-1 Positive Allosteric Modulator (PAM) J. Med. Chem. 2014, 57, 10192-10197 10.1021/jm501375c
90. 5) Positive Allosteric Modulators (PAMs) for the Treatment of Schizophrenia: An Historical Perspective and a Review of the Patent Literature Pharm. Pat. Anal. 2013, 2, 93-108 10.4155/ppa.12.82
91. Emmitte, K. A. Recent Advances in the Design and Development of Novel Negative Allosteric Modulators of mGlu5 ACS Chem. Neurosci. 2011, 2, 411-432 10.1021/cn2000266
92. 3H]-M-MPEP, a Potent, Subtype-Selective Radioligand for the Metabotropic Glutamate Receptor Subtype 5 Bioorg. Med. Chem. Lett. 2002, 12, 407-409 10.1016/S0960-894X(01)00767-3
93. 3H]-Methoxy-PEPy: Potent and Selective Radioligands for the Metabotropic Glutamate Subtype 5 (mGlu5) Receptor Bioorg. Med. Chem. Lett. 2003, 13, 351-1353 10.1016/S0960-894X(02)00997-6
94. 5). In Probe Reports from the NIH Molecular Libraries Program; National Center for Biotechnology Information: Bethesda, MD, 2010.
95. Milligan, G.; Smith, N. J. Allosteric Modulation of Heterodimeric G-Protein-Coupled Receptors Trends Pharmacol. Sci. 2007, 28, 615-620 10.1016/j.tips.2007.11.001
96. George, S. R.; Fan, T.; Xie, Z.; Tse, R.; Tam, V.; Varghese, G.; O'Dowd, B. F. Oligomerization of μ- and δ-Opioid Receptors. Generation of Novel Functional Properties J. Biol. Chem. 2000, 275, 26128-26135 10.1074/jbc.M000345200
97. Rashid, A. J.; So, C. H.; Kong, M. M. C.; Furtak, T.; El-Ghundi, M.; Cheng, R.; O'Dowd, B. F.; George, S. D1-D2 Dopamine Receptor Heterooligomers with Unique Pharmacology are Coupled to Rapid Activation of Gq/11 in the Striatum Proc. Natl. Acad. Sci. U. S. A. 2007, 104, 654-659 10.1073/pnas.0604049104
98. Ayoub, M. A.; Levoye, A.; Delagrange, P.; Jockers, R. Preferential Formation of MT1/MT2 Melatonin Receptor Heterodimers with Distinct Ligand Interaction Properties Compared with MT2 Homodimers Mol. Pharmacol. 2004, 66, 312-321 10.1124/mol.104.000398
99. Kostenis, E.; Milligan, G.; Christopoulos, A.; Sanchez-Ferrer, C. F.; Heringer-Walther, S.; Sexton, P. M.; Gembardt, F.; Kellett, E.; Martini, L.; Vanderheyden, P.; Schultheiss, H.-P.; Walther, T. G-Protein-Coupled Receptor Mas Is a Physiological Antagonist of the Angiotensin II Type 1 Receptor Circulation 2005, 111, 1806-1813 10.1161/01.CIR.0000160867.23556.7D
100. AbdAlla, S.; Lother, H.; Abdel-tawab, A. M.; Quitterer, U. The Angiotensin II AT2 Receptor is an AT1 Receptor Antagonist J. Biol. Chem. 2001, 276, 39721-39726 10.1074/jbc.M105253200
101. Levoye, A.; Dam, L.; Ayoub, M. A.; Guillaume, J.-L.; Couturier, C.; Delagrange, P.; Jockers, R. The Orphan GPR50 Receptor Specifically Inhibits MT1Melatonin Receptor Function Through Heterodimerization EMBO J. 2006, 25, 3012-3023 10.1038/sj.emboj.7601193
102. Milligan, G. The Role of Dimerisation in the Cellular Trafficking of G-Protein-Coupled Receptors Curr. Opin. Pharmacol. 2010, 10, 23-29 10.1016/j.coph.2009.09.010
103. Archbold, J. K.; Flanagan, J. U.; Watkins, H. A.; Gingell, J. J.; Hay, D. L. Structural Insights into RAMP Modification of Secretin Family G Protein-Coupled Receptors: Implications for Drug Development Trends Pharmacol. Sci. 2011, 32, 591-600 10.1016/j.tips.2011.05.007
104. Russell, F. A.; King, R.; Smillie, S.-J.; Kodji, X.; Brain, S. D. Calcitonin Gene-Related Peptide: Physiology and Pathophysiology Physiol. Rev. 2014, 94, 1099-1142 10.1152/physrev.00034.2013
105. Bomberger, J. M.; Parameswaran, N.; Spielman, W. S. Regulation of GPCR Trafficking by RAMPs Adv. Exp. Med. Biol. 2012, 744, 25-37 10.1007/978-1-4614-2364-5-3
106. Bomberger, J. M.; Parameswaran, N.; Hall, C. S.; Aiyar, N.; Spielman, W. S. Novel Function for Receptor Activity-Modifying Proteins (RAMPs) in Post-Endocytic Receptor Trafficking J. Biol. Chem. 2005, 280, 9297-9307 10.1074/jbc.M413786200
107. Hay, D. L.; Poyner, D. R.; Sexton, P. M. GPCR Modulation by RAMPs Pharmacol. Ther. 2006, 109, 173-197 10.1016/j.pharmthera.2005.06.015
108. Sexton, P. M.; Morfis, M.; Tilakarante, N.; Hay, D. L.; Udawela, M.; Christopoulos, G.; Christopoulos, A. Complexing Receptor Pharmacology: Modulation of Family B G Protein-Coupled Receptor Function by RAMPs Ann. N. Y. Acad. Sci. 2006, 1070, 90-104 10.1196/annals.1317.076
109. Kniazeff, J.; Prezeau, L.; Rondard, P.; Pin, J.-P.; Goudet, C. Dimers and Beyond: The Functional Puzzles of Class C GPCRs Pharmacol. Ther. 2011, 130, 9-25 10.1016/j.pharmthera.2011.01.006
110. Romano, C.; Yang, W. L.; O'Malley, K. L. Metabotropic Glutamate Receptor 5 is a Disulfide-Linked Dimer J. Biol. Chem. 1996, 271, 28612-28616 10.1074/jbc.271.45.28612
111. BR2 Nature 1998, 396, 674-679 10.1038/25348
112. Bai, M.; Trivedi, S.; Brown, E. M. Dimerization of the Extracellular Calcium-Sensing Receptor (CaR) on the Cell Surface of CaR-Transfected HEK293 Cells J. Biol. Chem. 1998, 273, 23605-23610 10.1074/jbc.273.36.23605
113. B-Receptor Subtypes Assemble into Functional Heteromeric Complexes Nature 1998, 396, 683-687 10.1038/25360
114. B Receptor Nature 1998, 396, 679-682 10.1038/25354
115. Javitch, J. A. The Ants go Marching Two by Two: Oligomeric Structure of G-Protein-Coupled Receptors Mol. Pharmacol. 2004, 66, 1077-1082 10.1124/mol.104.006320
116. Zhao, G. Q.; Zhang, Y.; Hoon, M. A.; Chandrashekar, J.; Erlenbach, I.; Ryba, N. J. P.; Zuker, C. S. The Receptors for Mammalian Sweet and Umami Taste Cell 2003, 115, 255-266 10.1016/S0092-8674(03)00844-4
117. B Receptors: Mechanism of Action and Therapeutic Perspective Curr. Neuropharmacol. 2007, 5, 195-201 10.2174/157015907781695919
118. B Receptor Biochem. Pharmacol. 2004, 68, 1565-1572 10.1016/j.bcp.2004.06.035
119. B Receptor J. Biol. Chem. 2004, 279, 29085-29091 10.1074/jbc.M400930200
120. Xu, H.; Staszewski, L.; Tang, H.; Adler, E.; Zoller, M.; Li, X. Different Functional Roles of T1R Subunits in the Heteromeric Taste Receptors Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 14258-14263 10.1073/pnas.0404384101
121. Jiang, P.; Cui, M.; Zhao, B.; Snyder, L. A.; Benard, L. M. J.; Osman, R.; Max, M.; Margolskee, R. F. Identification of the Cyclamate Interaction Site Within the Transmembrane Domain of the Human Sweet Taste Receptor Subunit T1R3 J. Biol. Chem. 2005, 280, 34296-34305 10.1074/jbc.M505255200
122. Jiang, P.; Cui, M.; Ji, Q.; Snyder, L.; Liu, Z.; Benard, L.; Margolskee, R. F.; Osman, R.; Max, M. Molecular Mechanisms of Sweet Receptor Function Chem. Senses 2005, 30 (Suppl 1) i17-i18 10.1093/chemse/bjh091
123. Jiang, P.; Cui, M.; Zhao, B.; Liu, Z.; Snyder, L. A.; Benard, L. M. J.; Osman, R.; Margolskee, R. F.; Max, M. Lactisole Interacts with the Transmembrane Domains of Human T1R3 to Inhibit Sweet Taste J. Biol. Chem. 2005, 280, 15238-15246 10.1074/jbc.M414287200
124. Winnig, M.; Bufe, B.; Meyerhof, W. Valine 738 and Lysine 735 in the Fifth Transmembrane Domain of rTas1r3Mediate Insensitivity Towards Lactisole of the Rat Sweet Taste Receptor BMC Neurosci. 2005, 6, 22-30 10.1186/1471-2202-6-22
125. Cui, M.; Jiang, P.; Maillet, E.; Max, M.; Margolskee, R. F.; Osman, R. The Heterodimeric Sweet Taste Receptor has Multiple Potential Ligand Binding Sites Curr. Pharm. Des. 2006, 12, 4591-4600 10.2174/138161206779010350
126. Romano, C.; Yang, W. L.; O'Malley, K. L. Metabotropic Glutamate Receptor 5 is a Disulfide-Linked Dimer J. Biol. Chem. 1996, 271, 28612-2866 10.1074/jbc.271.45.28612
127. Kunishima, N.; Shimada, Y.; Tsuji, Y.; Sato, T.; Yamamoto, M.; Kumasaka, T.; Nakanishi, S.; Jingami, H.; Morikawa, K. Structural Basis of Glutamate Recognition by a Dimeric Metabotropic Glutamate Receptor Nature 2000, 407, 971-977 10.1038/35039564
128. Tsuji, Y.; Shimada, Y.; Takeshita, T.; Kajimura, N.; Nomura, S.; Sekiyama, N.; Otomo, J.; Usukura, J.; Nakanishi, S.; Jingami, H. Cryptic Dimer Interface and Domain Organization of the Extracellular Region of Metabotropic Glutamate Receptor Subtype 1 J. Biol. Chem. 2000, 275, 28144-28151 10.1074/jbc.M003226200
129. Niswender, C. M.; Conn, P. J. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322 10.1146/annurev.pharmtox.011008.145533
130. Doumazane, E.; Scholler, P.; Zwier, J. M.; Trinquet, E.; Rondard, P.; Pin, J.-P. A New Approach to Analyze Cell Surface Protein Complexes Reveals Specific Heterodimeric Metabotropic Glutamate Receptors FASEB J. 2011, 25, 66-77 10.1096/fj.10-163147
131. Kammermeier, P. J. Functional and Pharmacological Characteristics of Metabotropic Glutamate Receptors 2/4 Heterodimers Mol. Pharmacol. 2012, 82, 438-447 10.1124/mol.112.078501
132. Lundstrom, L.; Bissantz, C.; Beck, J.; Wettstein, J. G.; Woltering, T. J.; Wichmann, J.; Gatti, S. Structural Determinants of Allosteric Antagonism at Metabotropic Glutamate Receptor 2: Mechanistic Studies with New Potent Negative Allosteric Modulators Br. J. Pharmacol. 2011, 164, 521-537 10.1111/j.1476-5381.2011.01409.x
133. Hlavackova, V.; Goudet, C.; Kniazeff, J.; Zikova, A.; Maurel, D.; Vol, C.; Trojanova, J.; Prézeau, L.; Pin, J.-P.; Blahos, J. Evidence for a Single Heptahelical Domain being Turned on Upon Activation of a Dimeric GPCR EMBO J. 2005, 24, 499-509 10.1038/sj.emboj.7600557
134. Yin, S.; Noetzel, M. J.; Johnson, K. A.; Zamorano, R.; Jalan-Sakrikar, N.; Gregory, K. J.; Conn, P. J.; Niswender, C. M. Selective Actions of Novel Allosteric Modulators Reveal Functional Heteromers of Metabotropic Glutamate Receptors in the CNS J. Neurosci. 2014, 34, 79-94 10.1523/JNEUROSCI.1129-13.2014
135. Ortuno, D.; Cheng, C.; Weiss, M.; Bergeron, M.; Shanker, Y. Identification and Characterization of a Potent and Selective Positive Allosteric Modulator of mGluR4. Presented at Neuroscience 2008, Washington, DC, 2008; Poster 823.27/C40.
136. Bennouar, K. E.; Uberti, M. A.; Melon, C.; Bacolod, M. D.; Jimenez, H. N.; Cajina, M.; Kerkerian-Le Goff, L.; Doller, D.; Gubellini, P. Synergy between l -DOPA and a Novel Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4: Implications for Parkinson's Disease Treatment and Dyskinesia Neuropharmacology 2013, 66, 158-169 10.1016/j.neuropharm.2012.03.022
137. Rovira, X.; Malhaire, F.; Scholler, P.; Rodrigo, J.; Gonzalez-Bulnes, P.; Llebaria, A.; Pin, J. P.; Giraldo, J.; Goudet, C. Overlapping Binding Sites Drive Allosteric Agonism and Positive Cooperativity in Type 4 Metabotropic Glutamate Receptors FASEB J. 2015, 29, 116-130 10.1096/fj.14-257287
138. Valenti, O.; Mannaioni, G.; Seabrook, G. R.; Marino, M. J. Group III Metabotropic Glutamate-Receptor-Mediated Modulation of Excitatory Transmission in Rodent Substantia Nigra Pars Compacta Dopamine Neurons J. Pharmacol. Exp. Ther. 2005, 313, 1296-1304 10.1124/jpet.104.080481
139. Lovinger, D. M.; McCool, B. A. Metabotropic Glutamate Receptor-Mediated Presynaptic Depression at Corticostriatal Synapses Involves mGluR2 or 3 J. Neurophysiol. 1995, 73, 1076-1083
140. Kahn, L.; Alonso, G.; Robbe, D.; Bockaert, J.; Manzoni, O. J. Group 2 Metabotropic Glutamate Receptors Induced Long Term Depression in Mouse Striatal Slices Neurosci. Lett. 2001, 316, 178-182 10.1016/S0304-3940(01)02397-7
141. Martella, G.; Platania, P.; Vita, D.; Sciamanna, G.; Cuomo, D.; Tassone, A.; Tscherter, A.; Kitada, T.; Bonsi, P.; Shen, J. et al. Enhanced Sensitivity to Group II mGlu Receptor Activation at Corticostriatal Synapses in Mice Lacking the Familial Parkinsonism-Linked genes PINK1 or Parkin Exp. Neurol. 2009, 215, 388-396 10.1016/j.expneurol.2008.11.001
142. Picconi, B.; Pisani, A.; Centonze, D.; Battaglia, G.; Storto, M.; Nicoletti, F.; Bernardi, G.; Calabresi, P. Striatal Metabotropic Glutamate Receptor Function Following Experimental Parkinsonism and Chronic Levodopa Treatment Brain 2002, 125, 2635-2645 10.1093/brain/awf269
143. Gubellini, P.; Melon, C.; Dale, E.; Doller, D.; Kerkerian-Le Goff, L. Distinct Effects of mGlu4 Receptor Positive Allosteric Modulators at Corticostriatal vs. Striatopallidal Synapses May Differentially Contribute to their Antiparkinsonian Action Neuropharmacology 2014, 85, 166-177 10.1016/j.neuropharm.2014.05.025
144. Marino, M. J.; Williams, D. L., Jr; O'Brien, J. A.; Valenti, O.; McDonald, T. P.; Clements, M. K.; Wang, R.; DiLella, A. G.; Hess, J. F.; Kinney, G. G. et al. Allosteric Modulation of Group III Metabotropic Glutamate Receptor 4: A Potential Approach to Parkinson's Disease Treatment Proc. Natl. Acad. Sci. U. S. A. 2003, 100, 13668-13673 10.1073/pnas.1835724100
145. Conn, P. J.; Battaglia, G.; Marino, M. J.; Nicoletti, F. Metabotropic Glutamate Receptors in the Basal Ganglia Motor Circuit Nat. Rev. Neurosci. 2005, 6, 787-798 10.1038/nrn1763
146. Jones, C. K.; Bubser, M.; Thompson, A. D.; Dickerson, J. W.; Turle-Lorenzo, N.; Amalric, M.; Blobaum, A. L.; Bridges, T. M.; Morrison, R. D.; Jadhav, S. et al. The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l -DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson's Disease J. Pharmacol. Exp. Ther. 2012, 340, 404-421 10.1124/jpet.111.187443
147. Jones, C. K.; Engers, D. W.; Thompson, A. D.; Field, J. R.; Blobaum, A. L.; Lindsley, S. R.; Zhou, Y.; Gogliotti, R. D.; Jadhav, S.; Zamorano, R. et al. Discovery, Synthesis, and Structure-Activity Relationship Development of a Series of N-4-(2,5-Dioxopyrrolidin-1-yl)phenylpicolinamides (VU0400195, ML182): Characterization of a Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 (mGlu(4)) with Oral Efficacy in an Antiparkinsonian Animal Model J. Med. Chem. 2011, 54, 7639-7647 10.1021/jm200956q
148. Niswender, C. M.; Johnson, K. A.; Weaver, C. D.; Jones, C. K.; Xiang, Z.; Luo, Q.; Rodriguez, A. L.; Marlo, J. E.; de Paulis, T.; Days, E.L.n et al. Discovery, Characterization, and Antiparkinsonian Effect of Novel Positive Allosteric Modulators of Metabotropic Glutamate Receptor 4 Mol. Pharmacol. 2008, 74, 1345-1358 10.1124/mol.108.049551
149. Le Poul, E.; Boléa, C.; Girard, F.; Poli, S.; Charvin, D.; Campo, B.; Bortoli, J.; Bessif, A.; Luo, B.; Koser, A. J. et al. A Potent and Selective Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator Improves Movement in Rodent Models of Parkinson's Disease J. Pharmacol. Exp. Ther. 2012, 343, 167-177 10.1124/jpet.112.196063
150. Picconi, B.; Centonze, D.; Rossi, D.; Bernardi, G.; Calabresi, P. Therapeutic Doses of l -Dopa Reverse Hypersensitivity of Corticostriatal D2-Dopamine Receptors and Glutamatergic Overactivity in Experimental Parkinsonism Brain 2004, 127, 1661-1669 10.1093/brain/awh190
151. Centonze, D.; Gubellini, P.; Rossi, S.; Picconi, B.; Pisani, A.; Bernardi, G.; Calabresi, P.; Baunez, C. Subthalamic Nucleus Lesion Reverses Motor Abnormalities and Striatal Glutamatergic Overactivity in Experimental Parkinsonism Neuroscience 2005, 133, 831-840 10.1016/j.neuroscience.2005.03.006
152. Garcia, B. G.; Neely, M. D.; Deutch, A. Y. Cortical Regulation of Striatal Medium Spiny Neuron Dendritic Remodeling in Parkinsonism: Modulation of Glutamate Release Reverses Dopamine Depletion-Induced Dendritic Spine Loss Cereb. Cortex 2010, 20, 2423-32 10.1093/cercor/bhp317
153. Picconi, B.; Centonze, D.; Hakansson, K.; Bernardi, G.; Greengard, P.; Fisone, G.; Cenci, M. A.; Calabresi, P. Loss of Bidirectional Striatal Synaptic Plasticity in l -DOPA-Induced Dyskinesia Nat. Neurosci. 2003, 6, 501-506 10.1038/nn1040
154. Picconi, B.; Bagetta, V.; Ghiglieri, V.; Paillè, V.; Di Filippo, M.; Pendolino, V.; Tozzi, A.; Giampa, C.; Fusco, F. R.; Sgobio, C.; Calabresi, P. Inhibition of Phosphodiesterases Rescues Striatal Long-Term Depression and Reduces Levodopa-Induced Dyskinesia Brain 2011, 134, 375-387 10.1093/brain/awq342
155. Kennedy, J. P.; Williams, L.; Bridges, T. M.; Daniels, R. N.; Weaver, D.; Lindsley, C. W. Application of Combinatorial Chemistry Science on Modern Drug Discovery J. Comb. Chem. 2008, 10, 345-354 10.1021/cc700187t
156. 1 Receptors Found in Schizophrenics J. Med. Chem. 2015, 58, 7959-7971 10.1021/acs.jmedchem.5b00727
157. 5 Selective NAM J. Med. Chem. 2013, 56, 9351-9355 10.1021/jm4013246
158. 5 NAM MLPCN probe ML375: Tactics and Challenges Bioorg. Med. Chem. Lett. 2015, 25, 690-694 10.1016/j.bmcl.2014.11.082
159. 5 PAM Bioorg. Med. Chem. Lett. 2012, 22, 3921-3925 10.1016/j.bmcl.2012.04.112
160. 3 Selective and CNS Penetrant Negative Allosteric Modulator (NAM) J. Med. Chem. 2013, 56, 5208-5212 10.1021/jm400439t
161. 1 Muscarinic Receptor J. Med. Chem. 2013, 56, 5151-5172 10.1021/jm400540b
162. 1 Receptors Derived from Deleterious GRM1 Mutations Found in Schizophrenics ACS Chem. Biol. 2014, 9, 2334-2346 10.1021/cb500560h
163. 1 PAM Bioorg. Med. Chem. Lett. 2010, 20, 1972-1975 10.1016/j.bmcl.2010.01.109
164. 5 PAM Bioorg. Med. Chem. Lett. 2010, 20, 558-562 10.1016/j.bmcl.2009.11.089
165. 5 Positive Allosteric Modulator Derived from a Series of 5-Trifluoromethoxy N-Benzyl Isatins J. Med. Chem. 2009, 52, 3445-3448 10.1021/jm900286j
166. Mathiesen, J. M.; Svendsen, N.; Brauner-Osborne, H.; Thomsen, C.; Ramirez, M. T. Positive Allosteric Modulation of the Human Metabotropic Glutamate Receptor 4 (hmGluR4) by SIB-1893 and MPEP Br. J. Pharmacol. 2003, 138, 1026-1030 10.1038/sj.bjp.0705159
167. Maj, M.; Bruno, V.; Dragic, Z.; Yamamoto, R.; Battaglia, G.; Inderbitzin, W.; Stoehr, N.; Stein, T.; Gasparini, F.; Kuhn, R.; Nicoletti, F.; Flor, P. J. (-)-PHCCC, a Positive Allosteric Modulator of mGluR4: Characterization, Mechanism of Action, and Neuroprotection Neuropharmacology 2003, 45, 895-906 10.1016/S0028-3908(03)00271-5
168. Annoura, H.; Fukunaga, A.; Uesugi, M.; Tatsuoka, T.; Horikawa, Y. A Novel Class of Antagonists for Metabotropic Glutamate Receptors, 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylates Bioorg. Med. Chem. Lett. 1996, 6, 763-766 10.1016/0960-894X(96)00104-7
169. O'Brien, J. A.; Lemaire, W.; Wittmann, M.; Jacobson, M. A.; Ha, S. N.; Wisnoski, D. D.; Lindsley, C. W.; Schaffhauser, H. J.; Rowe, B.; Sur, C. et al. A Novel Selective Allosteric Modulator Potentiates the Activity of Native Metabotropic Glutamate Receptor Subtype 5 in Rat Forebrain J. Pharmacol. Exp. Ther. 2004, 309, 568-577 10.1124/jpet.103.061747
170. Lazareno, S.; Dolezal, V.; Popham, A.; Birdsall, N. J. Thiochrome Enhances Acetylcholine Affinity at Muscarinic M4 Receptors: Receptor Subtype Selectivity via Cooperativity Rather than Affinity Mol. Pharmacol. 2004, 65, 257-266 10.1124/mol.65.1.257
171. Fukuda, J.; Suzuki, G.; Kimura, T.; Nagatomi, Y.; Ito, S.; Kawamoto, H.; Ozaki, S.; Ohta, H. Identification of a Novel Transmembrane Domain Involved in the Negative Modulation of mGluR1 Using a Newly Discovered Allosteric mGluR1 Antagonist, 3-Cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one Neuropharmacology 2009, 57, 438-445 10.1016/j.neuropharm.2009.06.017
172. Muhlemann, A.; Ward, N. A.; Kratochwil, N.; Diener, C.; Fischer, C.; Stucki, A.; Jaeschke, G.; Malherbe, P.; Porter, R. H. Determination of Key Amino Acids Implicated in the Actions of Allosteric Modulation by 3,3′-Difluorobenzaldazine on Rat mGlu5 Receptors Eur. J. Pharmacol. 2006, 529, 95-104 10.1016/j.ejphar.2005.11.008
173. Gregory, K. J.; Nguyen, E. D.; Malosh, C.; Mendenhall, J. L.; Zic, J. Z.; Bates, B. S.; Noetzel, M. J.; Squire, E. F.; Turner, E. M.; Rook, J. M. et al. Identification of Specific Ligand-Receptor Interactions that Govern Binding and Cooperativity of Diverse Modulators to a Common Metabotropic Glutamate Receptor 5 Allosteric Site ACS Chem. Neurosci. 2014, 5, 282-295 10.1021/cn400225x
174. 5) Positive Allosteric Modulator (PAM) Binding Pocket: Discovery of Point Mutations that Engender a ″Molecular Switch″ in PAM Pharmacology Mol. Pharmacol. 2013, 83, 991-1006 10.1124/mol.112.083949
175. Turlington, M.; Noetzel, M. J.; Chun, A.; Zhou, Y.; Gogliotti, R. D.; Nguyen, E. D.; Gregory, K. J.; Vinson, P. N.; Rook, J. M.; Gogi, K. K. et al. Exploration of Allosteric Agonism Structure-Activity Relationships Within an Acetylene Series of Metabotropic Glutamate Receptor 5 (mGlu5) Positive Allosteric Modulators (PAMs): Discovery of 5-((3-Fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254) J. Med. Chem. 2013, 56, 7976-7996 10.1021/jm401028t
176. 5 Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile) J. Med. Chem. 2015, 58, 6653-6664 10.1021/acs.jmedchem.5b00892
177. Dore, A. S.; Okrasa, K.; Patel, J. C.; Serrano-Vega, M.; Bennett, K.; Cooke, R. M.; Errey, J. C.; Jazayeri, A.; Khan, S.; Tehan, B. et al. Structure of Class C GPCR Metabotropic Glutamate Receptor 5 Transmembrane Domain Nature 2014, 511, 557-562 10.1038/nature13396
178. Wu, H.; Wang, C.; Gregory, K. J.; Han, G. W.; Cho, H. P.; Xia, Y.; Niswender, C. M.; Katritch, V.; Meiler, J.; Cherezov, V. et al. Structure of a Class C GPCR Metabotropic Glutamate Receptor 1 Bound to an Allosteric Modulator Science 2014, 344, 58-64 10.1126/science.1249489
179. Niswender, C. M.; Conn, P. J. Metabotropic Glutamate Receptors: Physiology, Pharmacology, and Disease Annu. Rev. Pharmacol. Toxicol. 2010, 50, 295-322 10.1146/annurev.pharmtox.011008.145533
180. Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological Agents Acting at Subtypes of Metabotropic Glutamate Receptors Neuropharmacology 1999, 38, 1431-1476 10.1016/S0028-3908(99)00092-1
181. Conn, P. J.; Pin, J.-P. Pharmacology and Functions of Metabotropic Glutamate Receptors Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237 10.1146/annurev.pharmtox.37.1.205
182. Stauffer, S. R. Progress Toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5) ACS Chem. Neurosci. 2011, 2, 450-470 10.1021/cn2000519
183. Owen, D. R. Recent Advances in the Medicinal Chemistry of the Metabotropic Glutamate Receptor 1 (mGlu1) ACS Chem. Neurosci. 2011, 2, 394-401 10.1021/cn2000124
184. Urwyler, S. Allosteric Modulation of Family C G-Protein-Coupled Receptors: From Molecular Insights to Therapeutic Perspectives Pharmacol. Rev. 2011, 63, 59-126 10.1124/pr.109.002501
185. Knoflach, F.; Mutel, V.; Jolidon, S.; Kew, J. N.; Malherbe, P.; Vieira, E.; Wichmann, J.; Kemp, J. A. Positive Allosteric Modulators of Metabotropic Glutamate 1 Receptor: Characterization, Mechanism of Action and Binding Site Proc. Natl. Acad. Sci. U. S. A. 2001, 98, 13402-13407 10.1073/pnas.231358298
186. Vieira, E.; Huwyler, J.; Jolidon, S.; Knoflach, F.; Mutel, V.; Wichmann, J. 9H-Xanthene-9-carboxylic acid [1,2,4]oxadiazol-3-yl and (2H-tertazol-5-yl)-amides as Potent, Orally Available mGlu1 Enhancers Bioorg. Med. Chem. Lett. 2005, 15, 4628-4631 10.1016/j.bmcl.2005.05.135
187. Vieira, E.; Huwyler, J.; Jolidon, S.; Knoflach, F.; Mutel, V.; Wichmann, J. Fluorinated 9H-Xanthene-9-carboxylic Acid Oxazol-2-yl Amides as Potent, Orally Available mGlu1 Enhancers Bioorg. Med. Chem. Lett. 2009, 19, 1666-1669 10.1016/j.bmcl.2009.01.108
188. Hemstapat, K.; de Paulis, T.; Chen, Y.; Brady, A. E.; Grover, V. K.; Alagille, D.; Tamagnan, G. D.; Conn, P. J. A Novel Class of Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 1 Interact with a Site Distinct From that of Negative Allosteric Modulators Mol. Pharmacol. 2006, 70, 616-626 10.1124/mol.105.021857
189. Fazio, F.; Notartomaso, S.; Aronica, E.; Storto, M.; Battaglia, G.; Vieira, E.; Gatti, S.; Bruno, V.; Biagioni, F.; Gradini, R. et al. Switch in the Expression of mGlu1 and mGlu5Metabotropic Glutamate Receptors in the Cerebellum of Mice Developing Experimental Autoimmune Encephalomyelitis and in Autoptic Cerebellear Samples From Patients with Multiple Sclerosis Neuropharmacology 2008, 55, 491-499 10.1016/j.neuropharm.2008.06.066
190. Ngomba, R. T.; Santolini, I.; Biagioni, F.; Molinaro, G.; Simonyi, A.; van Rijn, C. M.; D'Amore, V.; Mastroiacovo, F.; Olivieri, G.; Gradini, R. et al. Protective Role for Type-1 Metabotropic Glutamate Receptors Against Spike and Wave Discharges in in the WAG/Rij Model of Absence Epilepsy Neuropharmacology 2011, 60, 1281-1291 10.1016/j.neuropharm.2011.01.007
191. D'Amore, V.; Santolini, I.; Celli, R.; Lionetto, L.; De Fusco, A.; Simmaco, M.; van Rijn, C. M.; Vieira, E.; Stauffer, S. R.; Conn, P. J. et al. Head-to-Head Comparison of mGlu1 and mGlu5 Receptor Activation in Chronic Treatment of Absence Epilepsy in WAG/Rij Rats Neuropharmacology 2014, 85, 91-103 10.1016/j.neuropharm.2014.05.005
192. Notartomaso, S.; Zappulla, C.; Biagioni, F.; Cannella, M.; Bucci, D.; Mascio, G.; Scarselli, P.; Fazio, F.; Weisz, F.; Lionetto, L. et al. Pharmacological Enhancement of mGlu1Metabotropic Glutamate Receptors Causes a Prolonged Symptomatic Benefit in a Mouse Model of Spinocerebellar Ataxia Type 1 Mol. Brain 2013, 6, 48-56 10.1186/1756-6606-6-48
193. Frank, R. A. W.; McRae, A. F.; Pocklington, A. J.; van de Lagemaat, L. N.; Navarro, P.; Croning, M. D. R.; Komiyama, N. H.; Bradley, S. J.; Challiss, R. A. J.; Armstrong, J. D. et al. Clustered Coding Variants in the Glutamate Receptor Complexes of Individuals with Schizophrenia and Bipolar Disorder PLoS One 2011, 6, e19011 10.1371/journal.pone.0019011
194. Ayoub, M. A.; Angelicheva, D.; Vile, D.; Chandler, D.; Morar, B.; Cavanaugh, J. A.; Visscher, P. M.; Jablensky, A.; Pfleger, K. D. G.; Kalaydjieva, L. Deleterious GRM1Mutations in Schizophrenia PLoS One 2012, 7, e32849 10.1371/journal.pone.0032849
195. Williams, R.; Zhou, Y.; Niswender, C. M.; Luo, Q.; Conn, P. J.; Lindsley, C. W.; Hopkins, C. R. Re-exploration of the PHCCC Scaffold: Discovery of Improved Positive Allosteric Modulators of mGluR4 ACS Chem. Neurosci. 2010, 1, 411-419 10.1021/cn9000318
196. Garcia-Barrantes, P. M.; Cho, H. P.; Blobaum, A. L.; Niswender, C. M.; Conn, P. J.; Lindsley, C. W. Lead Optimization of the VU0486321 Series of mGlu1 PAMs. Part 1: SAR of Modifications to the Central Aryl Core Bioorg. Med. Chem. Lett. 2015, 25, 5107-5110 10.1016/j.bmcl.2015.10.013
197. Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological Agents Acting at Subtypes of Metabotropic Glutamate Receptors Neuropharmacology 1999, 38, 1431-1476 10.1016/S0028-3908(99)00092-1
198. Conn, P. J.; Pin, J.-P. Pharmacology and Functions of Metabotropic Glutamate Receptors Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237 10.1146/annurev.pharmtox.37.1.205
199. D'Antoni, S.; Berretta, A.; Bonaccorso, C. M.; Bruno, V.; Aronica, E.; Nicoletti, F.; Catania, M. V. Metabotropic Glutamate Receptors in Glial Cells Neurochem. Res. 2008, 33, 2436-2443 10.1007/s11064-008-9694-9
200. Chaki, S.; Ago, Y.; Palucha-Paniewiera, A.; Matrisciano, F.; Pilc, A. mGlu2/3 and mGlu5 Receptors: Potential Targets for Novel Antidepressants Neuropharmacology 2013, 66, 40-52 10.1016/j.neuropharm.2012.05.022
201. Palucha, A.; Pilc, A. Metabotropic Glutamate Receptor Ligands as Possible Anxiolytic and Antidepressant Drugs Pharmacol. Ther. 2007, 115, 116-147 10.1016/j.pharmthera.2007.04.007
202. Monn, J. A.; Valli, M. J.; Massey, S. M.; Wright, R. A.; Salhoff, C. R.; Johnson, B. G.; Howe, T.; Alt, C. A.; Rhodes, G. A.; Robey, R. L. et al. Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties J. Med. Chem. 1997, 40, 528-537 10.1021/jm9606756
203. Monn, J. A.; Valli, M. J.; Massey, S. M.; Hansen, M. M.; Kress, T. J.; Wepsiec, J. P.; Harkness, A. R.; Grutsch, J. L., Jr.; Wright, R. A.; Johnson, B. G. et al. Synthesis, Pharmacological Characterization, and Molecular Modeling of Heterobicyclic Amino Acids Related to (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): Identification of Two New Potent, Selective, and Systemically Active Agonists for Group II Metabotropic Glutamate Receptors J. Med. Chem. 1999, 42, 1027-1040 10.1021/jm980616n
204. Swanson, C. J.; Bures, M.; Johnson, M. P.; Linden, A.-M.; Monn, J. A.; Schoepp, D. D. Metabotropic Glutamate Receptors as Novel Targets for Anxiety and Stress Disorders Nat. Rev. Drug Discovery 2005, 4, 131-146 10.1038/nrd1630
205. Tizzano, J. P.; Griffey, K. I.; Schoepp, D. D. The Anxiolytic Action of mGlu2/3 Receptor Agonist, LY354740, in the Fear-Potentiated Startle Model in Rats is Mechanistically Distinct from Diazepam Pharmacol., Biochem. Behav. 2002, 73, 367-374 10.1016/S0091-3057(02)00850-X
206. Kłodzińska, A.; Chojnacka-Wójcik, E.; Pałucha, A.; Brański, P.; Popik, P.; Pilc, A. Potential Anti-Anxiety, Anti-Addictive Effects of LY 354740, a Selective Group II Glutamate Metabotropic Receptors Agonist in Animal Models Neuropharmacology 1999, 38, 1831-1839 10.1016/S0028-3908(99)00066-0
207. Helton, D. R.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D.; Kallman, M. J. Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors J. Pharmacol. Exp. Ther. 1998, 284, 651-660
208. Adewale, A. S.; Platt, D. M.; Spealman, R. D. Pharmacological Stimulation of Group II Metabotropic Glutamate Receptors Reduces Cocaine Self-Administration and Cocaine-Induced Reinstatement of Drug Seeking in Squirrel Monkeys J. Pharmacol. Exp. Ther. 2006, 318, 922-931 10.1124/jpet.106.105387
209. Peters, J.; Kalivas, P. W. The Group II Metabotropic Glutamate Receptor Agonist, LY379268, Inhibits both Cocaine- and Food-Seeking Behavior in Rats Psychopharmacology 2006, 186, 143-149 10.1007/s00213-006-0372-9
210. Baptista, M. A. S.; Martin-Fardon, R.; Weiss, F. Preferential Effects of the Metabotropic Glutamate 2/3 Receptor Agonist LY379268 on Conditioned Reinstatement Versus Primary Reinforcement: Comparison Between Cocaine and a Potent Conventional Reinforce J. Neurosci. 2004, 24, 4723-4727 10.1523/JNEUROSCI.0176-04.2004
211. Corti, C.; Battaglia, G.; Molinaro, G.; Riozzi, B.; Pittaluga, A.; Corsi, M.; Mugnaini, M.; Nicoletti, F.; Bruno, V. The Use of Knock-Out Mice Unravels Distinct Roles for mGlu2 and mGlu3Metabotropic Glutamate Receptors in Mechanisms of Neurodegeneration/Neuroprotection J. Neurosci. 2007, 27, 8297-8308 10.1523/JNEUROSCI.1889-07.2007
212. Murray, T. K.; Messenger, M. J.; Ward, M. A.; Woodhouse, S.; Osborne, D. J.; Duty, S.; O'Neill, M. J. Evaluation of the mGluR2/3 Agonist LY379268 in Rodent Models of Parkinson's Disease Pharmacol., Biochem. Behav. 2002, 73, 455-466 10.1016/S0091-3057(02)00842-0
213. Bond, A.; Jones, N. M.; Hicks, C. A.; Whiffin, G. M.; Ward, M. A.; O'Neill, M. F.; Kingston, A. E.; Monn, J. A.; Ornstein, P. L.; Schoepp, D. D.; Lodge, D.; O'Neill, M. J. Neuroprotective Effects of LY379268, a Selective mGlu2/3 Receptor Agonist: Investigations into Possible Mechanism of Action in Vivo J. Pharmacol. Exp. Ther. 2000, 294, 800-809
214. Bond, A.; Ragumoorthy, N.; Monn, J. A.; Hicks, C. A.; Ward, M. A.; Lodge, D.; O'Neill, M. J. LY379268, a Potent and Selective Group II Metabotropic Glutamate Receptor Agonist, is Neuroprotective in Gerbil Global, but not Focal, Cerebral Ischemia Neurosci. Lett. 1999, 273, 191-194 10.1016/S0304-3940(99)00663-1
215. Coffey, D. S.; Hawk, M. K.; Pedersen, S. W.; Vaid, R. K. An Efficient Synthesis of LY544344·HCl: A Prodrug of mGluR2 Agonist LY354740 Tetrahedron Lett. 2005, 46, 7299-7302 10.1016/j.tetlet.2005.08.144
216. Rorick-Kehn, L. M.; Perkins, E. J.; Knitowski, K. M.; Hart, J. C.; Johnson, B. G.; Schoepp, D. D.; McKinzie, D. L. Improved Bioavailability of the mGlu2/3 Receptor Agonist LY354740 using a Prodrug Strategy: In Vivo Pharmacology of LY544344 J. Pharmacol. Exp. Ther. 2005, 316, 905-913 10.1124/jpet.105.091926
217. Dunayevich, E.; Erickson, J.; Levine, L.; Landbloom, R.; Schoepp, D. D.; Tollefson, G. D. Efficacy and Tolerability of an mGlu2/3 Agonist in the Treatment of Generalized Anxiety Disorder Neuropsychopharmacology 2008, 33, 1603-1610 10.1038/sj.npp.1301531
218. Kellner, M.; Muhtz, C.; Stark, K.; Yassouridis, A.; Arlt, J.; Wiedemann, K. Effects of a Metabotropic Glutamate2/3 Receptor Agonist (LY544344/LY354740) on Panic Anxiety Induced by Cholecystokinin Tetrapeptide in Healthy Humans: Preliminary Results Psychopharmacology 2005, 179, 310-315 10.1007/s00213-004-2025-1
219. Bergink, V.; Westenberg, H. G. M. Metabotropic Glutamate II Receptor Agonists in Panic Disorder: A Double Blind Clinical Trial with LY354740 Int. Clin. Psychopharmacol. 2005, 20, 291-293 10.1097/00004850-200511000-00001
220. Grillon, C.; Cordova, J.; Levine, L. R.; Morgan, C. A., III. Anxiolytic Effects of a Novel Group II Metabotropic Glutamate Receptor Agonist (LY354740) in the Fear-Potentiated Startle Paradigm in Humans Psychopharmacology 2003, 168, 446-454 10.1007/s00213-003-1444-8
221. Schoepp, D. D.; Wright, R. A.; Levine, L. R.; Gaydos, B.; Potter, W. Z. LY354740, and mGlu2/3 Receptor Agonist as a Novel Approach to Treat Anxiety/Stress Stress 2003, 6, 189-197 10.1080/1025389031000146773
222. Vinson, P. N.; Conn, P. J. Metabotropic Glutamate Receptors as Therapeutic Targets for Schizophrenia Neuropharmacology 2012, 62, 1461-1472 10.1016/j.neuropharm.2011.05.005
223. Fell, M. J.; McKinzie, D. L.; Monn, J. A.; Svensson, K. A. Group II Metabotropic Glutamate Receptor Agonists and Positive Allosteric Modulators as Novel Treatments for Schizophrenia Neuropharmacology 2012, 62, 1473-1483 10.1016/j.neuropharm.2011.06.007
224. Conn, P. J.; Lindsley, C. W.; Jones, C. K. Activation of Metabotropic Glutamate Receptors as a Novel Approach for the Treatment of Schizophrenia Trends Pharmacol. Sci. 2009, 30, 25-31 10.1016/j.tips.2008.10.006
225. Chaki, S. Group II Metabotropic Glutamate Receptor Agonists as a Potential Drug for Schizophrenia Eur. J. Pharmacol. 2010, 639, 59-66 10.1016/j.ejphar.2009.12.041
226. Rorick-Kehn, L. M.; Johnson, B. G.; Burkey, J. L.; Wright, R. A.; Calligaro, D. O.; Marek, G. J.; Nisenbaum, E. S.; Catlow, J. T.; Kingston, A. E.; Giera, D. D. et al. Pharmacological and Pharmacokinetic Properties of a Structurally Novel, Potent, and Selective Mmetabotropic Glutamate 2/3 Receptor Agonist: In Vitro Characterization of Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039) J. Pharmacol. Exp. Ther. 2007, 321, 308-317 10.1124/jpet.106.110809
227. Mezler, M.; Geneste, H.; Gault, L.; Marek, G. J. LY-2140023, a Prodrug of the Group II Metabotropic Glutamate Receptor Agonist LY-404039 for the Potential Treatment of Schizophrenia Curr. Opin. Invest. Drugs 2010, 11, 833-845
228. Patil, S. T.; Zhang, L.; Martenyi, F.; Lowe, S. L.; Jackson, K. A.; Andreev, B. V.; Avedisova, A. S.; Bardenstein, L. M.; Gurovich, I. Y.; Morozova, M. A. et al. Activation of mGlu2/3 Receptors as a New Approach to Treat Schizophrenia: A Randomized Phase 2 Clinical Trial Nat. Med. 2007, 13, 1102-1107 10.1038/nm1632
229. Adams, D. H.; Zhang, L.; Millen, B. A.; Kinon, B. J.; Gomez, J.-C. Pomaglumetad Methionil (LY2140023 Monohydrate) and Aripiprazole in Patients with Schizophrenia: A Phase 3, Multicenter, Double-Blind Comparison Schizophr. Res. Treat. 2014, 2014, 758212 10.1155/2014/758212
230. Downing, A. M.; Kinon, B. J.; Millen, B. A.; Zhang, L.; Liu, L.; Morozova, M. A.; Brenner, R.; Rayle, T. J.; Nisenbaum, L.; Zhao, F.; Gomez, J. C. A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 Monohydrate in Patients with Schizophrenia BMC Psychiatry 2014, 14 (351) 1-12 10.1186/s12888-014-0351-3
231. Stauffer, V. L.; Millen, B. A.; Andersen, S.; Kinon, B. J.; LaGrandeur, L.; Lindenmayer, J. P.; Gomez, J. C. Pomaglumetad Methionil: No Significant Difference as an Adjunctive Treatment for Patients with Prominent Negative Symptoms of Schizophrenia Compared to Placebo Schizophr. Res. 2013, 150, 434-441 10.1016/j.schres.2013.08.020
232. Adams, D. H.; Kinon, B. J.; Baygani, S.; Millen, B. A.; Velona, I.; Kollack-Walker, S.; Walling, D. P. A Long-Term, Phase 2, Multicenter, Randomized, Open-Label, Comparative Safety Study of Pomaglumetad Methionil (LY2140023 Monohydrate) Versus Atypical Antipsychotic Standard of Care in Patients with Schizophrenia BMC Psychiatry 2013, 13 (143) 143-152 10.1186/1471-244X-13-143
233. Kinon, B. J.; Gómez, J. C. Clinical Development of Pomaglumetad Methionil: A Non-Dopaminergic Treatment for Schizophrenia Neuropharmacology 2013, 66, 82-86 10.1016/j.neuropharm.2012.06.002
234. Kinon, B. J.; Zhang, L.; Millen, B. A.; Osuntokun, O. O.; Williams, J. E.; Kollack-Walker, S.; Jackson, K.; Kryzhanovskaya, L.; Jarkova, N. HBBI Study Group. A Multicenter, In-patient, Phase 2, Double-Blind, Placebo-Controlled Dose-Ranging Study of LY2140023 Monohydrate in Patients with DSM-IV Schizophrenia J. Clin. Psychopharmacol. 2011, 31, 349-355 10.1097/JCP.0b013e318218dcd5
235. Lilly Stops Phase III Development of Pomaglumetad Methionil for the Treatment of Schizophrenia Based on Efficacy Results (Press Release). Eli Lilly and Company, Aug 29, 2012; available at https://investor.lilly.com/releasedetail.cfm?ReleaseID=703018 (accessed Aug 31, 2015).
236. Célanire, S.; Sebhat, I.; Wichmann, J.; Mayer, S.; Schann, S.; Gatti, S. Novel Metabotropic Glutamate Receptor 2/3 Antagonists and Their Therapeutic Applications: A Patent Review (2005-Present) Expert Opin. Ther. Patents 2015, 25, 69-90 10.1517/13543776.2014.983899
237. Ornstein, P. L.; Bleisch, T. J.; Arnold, M. B.; Kennedy, J. H.; Wright, R. A.; Johnson, B. G.; Tizzano, J. P.; Helton, D. R.; Kallman, M. J.; Schoepp, D. D.; Hérin, M. 2-Substituted (2SR)-2-Amino-2-((1SR,2SR)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 2. Effects of Aromatic Substitution, Pharmacological Characterization, and Bioavailability J. Med. Chem. 1998, 41, 358-378 10.1021/jm970498o
238. Chaki, S.; Yoshikawa, R.; Hirota, S.; Shimazaki, T.; Maeda, M.; Kawashima, N.; Yoshimizu, T.; Yasuhara, A.; Sakagami, K.; Okuyama, S. et al. MGS0039: A Potent and Selective Group II Metabotropic Glutamate Receptor Antagonist with Antidepressant-Like Activity Neuropharmacology 2004, 46, 457-467 10.1016/j.neuropharm.2003.10.009
239. Bespalov, A. Y.; van Gaalen, M. M.; Sukhotina, I. A.; Wicke, K.; Mezler, M.; Schoemaker, H.; Gross, G. Behavioral Characterization of the mGlu group II/III Receptor Antagonist, LY-341495, in Animal Models of Anxiety and Depression Eur. J. Pharmacol. 2008, 592, 96-102 10.1016/j.ejphar.2008.06.089
240. Shimazaki, T.; Iijima, M.; Chaki, S. Anxiolytic-Like Activity of MGS0039, a Potent Group II Metabotropic Glutamate Receptor Antagonist, in a Marble-Burying Behavior Test Eur. J. Pharmacol. 2004, 501, 121-125 10.1016/j.ejphar.2004.08.016
241. Yoshimizu, T.; Shimazaki, T.; Ito, A.; Chaki, S. An mGluR2/3 Antagonist, MGS0039, Exerts Antidepressant and Anxiolytic Effects in Behavioral Models in Rats Psychopharmacology 2006, 186, 587-593 10.1007/s00213-006-0390-7
242. Higgins, G. A.; Ballard, T. M.; Kew, J. N.; Richards, J. G.; Kemp, J. A.; Adam, G.; Woltering, T.; Nakanishi, S.; Mutel, V. Pharmacological Manipulation of mGlu2 Receptors Influences Cognitive Performance in the Rodent Neuropharmacology 2004, 46, 907-917 10.1016/j.neuropharm.2004.01.018
243. Kim, S. H.; Steele, J. W.; Lee, S. W.; Clemenson, G. D.; Carter, T. A.; Treuner, K.; Gadient, R.; Wedel, P.; Glabe, C.; Barlow, C. et al. Proneurogenic Group II mGluR Antagonist Improves Learning and Reduces Anxiety in Alzheimer Aβ Oligomer mouse Mol. Psychiatry 2014, 19, 1235-1242 10.1038/mp.2014.87
244. 42 from Isolated Intact Nerve Terminals J. Neurosci. 2010, 30, 3870-3875 10.1523/JNEUROSCI.4717-09.2010
245. Yoshimizu, T.; Chaki, S. Increased Cell Proliferation in the Adult Mouse Hippocampus Following Chronic Administration of Group II Metabotropic Glutamate Receptor Antagonist, MGS0039 Biochem. Biophys. Res. Commun. 2004, 315, 493-496 10.1016/j.bbrc.2004.01.073
246. Gleason, S. D.; Li, X.; Smith, I. A.; Ephlin, J. D.; Wang, X. S.; Heinz, B. A.; Carter, J. H.; Baez, M.; Yu, J. et al. mGlu2/3 Agonist-Induced Hyperthermia: An in Vivo Assay for Detection of mGlu2/3 Receptor Antagonism and its Relation to Antidepressant-Like Efficacy in Mice CNS Neurol. Disord.: Drug Targets 2013, 12, 554-566 10.2174/18715273113129990079
247. Koike, H.; Fukumoto, K.; Iijima, M.; Chaki, S. Role of BDNF/TrkB Signaling in Antidepressant-Like Effects of a Group II Metabotropic Glutamate Receptor Antagonist in Animal Models of Depression Behav. Brain Res. 2013, 238, 48-52 10.1016/j.bbr.2012.10.023
248. Koike, H.; Iijima, M.; Chaki, S. Involvement of the Mammalian Target of Rapamycin Signaling in the Antidepressant-Like Effect of Group II Metabotropic Glutamate Receptor Antagonists Neuropharmacology 2011, 61, 1419-1423 10.1016/j.neuropharm.2011.08.034
249. Karasawa, J.; Shimazaki, T.; Kawashima, N.; Chaki, S. AMPA Receptor Stimulation Mediates the Antidepressant-Like Effect of a Group II Metabotropic Glutamate Receptor Antagonist Brain Res. 2005, 1042, 92-98 10.1016/j.brainres.2005.02.032
250. Iijima, M.; Koike, H.; Chaki, S. Effect of an mGlu2/3 Receptor Antagonist on Depressive Behavior Induced by Withdrawal From Chronic Treatment with Methamphetamine Behav. Brain Res. 2013, 246, 24-28 10.1016/j.bbr.2013.02.039
251. Markou, A. Metabotropic Glutamate Receptor Antagonists: Novel Therapeutics for Nicotine Dependence and Depression? Biol. Psychiatry 2007, 61, 17-22 10.1016/j.biopsych.2006.03.053
252. Ago, Y.; Yano, K.; Araki, R.; Hiramatsu, N.; Kita, Y.; Kawasaki, T.; Onoe, H.; Chaki, S.; Nakazato, A.; Hashimoto, H.; Baba, A.; Takuma, K.; Matsuda, T. Metabotropic Glutamate 2/3 Receptor Antagonists Improve Behavioral and Prefrontal Dopaminergic Alterations in the Chronic Corticosterone-Induced Depression Model in Mice Neuropharmacology 2013, 65, 29-38 10.1016/j.neuropharm.2012.09.008
253. Dwyer, J. M.; Lepack, A. E.; Duman, R. S. mGluR2/3 Blockade Produces Rapid and Long-Lasting Reversal of Anhedonia Caused by Chronic Stress Exposure J. Mol. Psychiatry 2013, 1, 15 10.1186/2049-9256-1-15
254. Trabanco, A. A.; Cid, J. M. mGluR2 Positive Allosteric Modulators: A Patent Review (2009-present) Expert Opin. Ther. Pat. 2013, 23, 629-647 10.1517/13543776.2013.777043
255. Sheffler, D. J.; Pinkerton, A. B.; Dahl, R.; Markou, A.; Cosford, N. D. P. Recent Progress in the Synthesis and Characterization of Group II Metabotropic Glutamate Receptor Allosteric Modulators ACS Chem. Neurosci. 2011, 2, 382-393 10.1021/cn200008d
256. Woolley, M. L.; Pemberton, D. J.; Bate, S.; Corti, C.; Jones, D. N. C. The mGlu2 but not the mGlu3 Receptor Mediates the Actions of the mGluR2/3 Agonist, LY379268, in Mouse Models Predictive of Antipsychotic Activity Psychopharmacology 2008, 196, 431-440 10.1007/s00213-007-0974-x
257. Fell, M. J.; Svensson, K. A.; Johnson, B. G.; Schoepp, D. D. Evidence for the Role of Metabotropic Glutamate (mGlu)2 not mGlu3 Receptors in the Preclinical Antipsychotic Pharmacology of the mGlu2/3 Receptor Agonist (-)-(1R,4S,5S,6S)-4-Amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic Acid (LY404039) J. Pharmacol. Exp. Ther. 2008, 326, 209-217 10.1124/jpet.108.136861
258. Johnson, M. P.; Baez, M.; Jagdmann, G. E., Jr.; Britton, T. C.; Large, T. H.; Callagaro, D. O.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D. Discovery of Allosteric Potentiators for the Metabotropic Glutamate 2 Receptor: Synthesis and Subtype Selectivity of N-(4-(2-Methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethylamine J. Med. Chem. 2003, 46, 3189-3192 10.1021/jm034015u
259. Galici, R.; Echemendia, N. G.; Rodriguez, A. L.; Conn, P. J. A Selective Allosteric Potentiator of Metabotropic Glutamate (mGlu) 2 Receptors has Effects Similar to an Orthosteric mGlu2/3 Receptor Agonist in Mouse Models Predictive of Antipsychotic Activity J. Pharmacol. Exp. Ther. 2005, 315, 1181-1187 10.1124/jpet.105.091074
260. Galici, R.; Jones, C. K.; Hempstapat, K.; Nong, Y.; Echemendia, N. G.; Williams, L. C.; de Paulis, T.; Conn, P. J. Biphenyl-indanone A, a Positive Allosteric Modulator of the Metabotropic Glutamate Receptor Subtype 2, Has Antipsychotic- and Anxiolytic-Like Effects in Mice J. Pharmacol. Exp. Ther. 2006, 318, 173-185 10.1124/jpet.106.102046
261. Ellaithy, A.; Younkin, J.; González-Maeso, J.; Logothetis, D. E. Positive Allosteric Modulators of Metabotropic Glutamate 2 Receptors in Schizophrenia Treatment Trends Neurosci. 2015, 38, 506-516 10.1016/j.tins.2015.06.002
262. Barrett, J. E. mGluR2-Positive Allosteric Modulators: Therapeutic Potential for Treating Cocaine Abuse? Neuropsychopharmacology 2010, 35, 2007-2008 10.1038/npp.2010.93
263. Conn, P. J.; Jones, C. K. Promise of mGluR2/3 Activators in Psychiatry Neuropsychopharmacology 2009, 34, 248-249 10.1038/npp.2008.156
264. Li, M.-L.; Hu, X.-Q.; Li, F.; Gao, W.-J. Perspectives on the mGluR2/3 Agonists as a Therapeutic Target for Schizophrenia: Still Promising or a Dead End? Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2015, 60, 66-76 10.1016/j.pnpbp.2015.02.012
265. Sidique, S.; Dhanya, R.-P.; Sheffler, D. J.; Nickols, H. H.; Yang, L.; Dahl, R.; Mangravita-Novo, A.; Smith, L. H.; D'Souza, M. S. et al. Orally Active Metabotropic Glutamate Subtype 2 Receptor Positive Allosteric Modulators: Structure-Activity Relationships and Assessment in a Rat Model of Nicotine Dependence J. Med. Chem. 2012, 55, 9434-9445 10.1021/jm3005306
266. Dhanya, R.-P.; Sheffler, D. J.; Dahl, R.; Davis, M.; Lee, P. S.; Yang, L.; Nickols, H. H.; Cho, H. P.; Smith, L. H.; D'Souza, M. S. et al. Design and Synthesis of Systemically Active Metabotropic Glutamate Subtype-2 and -3 (mGlu2/3) Receptor Positive Allosteric Modulators (PAMs): Pharmacological Characterization and Assessment in a Rat Model of Cocaine Dependence J. Med. Chem. 2014, 57, 4154-4172 10.1021/jm5000563
267. Cube, R. V.; Vernier, J. M.; Hutchinson, J. H.; Gardner, M. F.; James, J. K.; Rowe, B. A.; Schaffhauser, H.; Daggett, L.; Pinkerton, A. B. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)-phenoxy]butoxy}phenyl)propanoic Acid: A Brain Penetrant Allosteric Potentiator at the Metabotropic Glutamate Receptor 2 (mGluR2) Bioorg. Med. Chem. Lett. 2005, 15, 2389-2393 10.1016/j.bmcl.2005.02.078
268. Jin, X.; Semenova, S.; Yang, L.; Ardecky, R.; Sheffler, D. J.; Dahl, R.; Conn, P. J.; Cosford, N. D.; Markou, A. The mGluR2 Positive Allosteric Modulator BINA Decreases Cocaine Self-Administration and Cue-Induced Cocaine-Seeking and Counteracts Cocaine-Induced Enhancement of Brain Reward Function in Rats Neuropsychopharmacology 2010, 35, 2021-2036 10.1038/npp.2010.82
269. Hiyoshi, T.; Marumo, T.; Hikichi, H.; Tomishima, Y.; Urabe, H.; Tamita, T.; Iida, I.; Yasuhara, A.; Karasawa, J.; Chaki, S. Neurophysiologic and Antipsychotic Profiles of TASP0433864, a Novel Positive Allosteric Modulator of Metabotropic Glutamate 2 Receptor J. Pharmacol. Exp. Ther. 2014, 351, 642-653 10.1124/jpet.114.218651
270. Garbaccio, R. M.; Brnardic, E. J.; Fraley, M. E.; Hartman, G. D.; Hutson, P. H.; O'Brien, J. A.; Magliaro, B. C.; Uslaner, J. M.; Huszar, S. L.; Fillgrove, K. L. et al. Discovery of Oxazolobenzimidazoles as Positive Allosteric Modulators for the mGluR2 Receptor ACS Med. Chem. Lett. 2010, 1, 406-410 10.1021/ml100115a
271. Tresadern, G.; Cid, J. M.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; García, A.; Matesanz, E.; Linares, M. L.; Oehlrich, D.; Lavreysen, H. et al. Scaffold Hopping from Pyridones to Imidazo[1,2-a]pyridines. New Positive Allosteric Modulators of Metabotropic glutamate 2 receptor Bioorg. Med. Chem. Lett. 2010, 20, 175-179 10.1016/j.bmcl.2009.11.008
272. Trabanco, A. A.; Tresadern, G.; Macdonald, G. J.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; García, A.; Linares, M. L.; Alonso de Diego, S. A.; Alonso, J. M. et al. Imidazo[1,2-a]pyridines: Orally Active Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor J. Med. Chem. 2012, 55, 2688-2701 10.1021/jm201561r
273. Cid, J. M.; Tresadern, G.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Iturrino, L.; Linares, M. L.; Garcia, A.; Andrés, J. I.; Macdonald, G. J. et al. Discovery of 3-Cyclopropylmethyl-7-(4-phenylpiperidin-1-yl)-8-trifluoromethyl[1,2,4]triazolo[4,3-a]pyridine (JNJ-42153605): A Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor J. Med. Chem. 2012, 55, 8770-8789 10.1021/jm3010724
274. 2 Receptor-Mediated Modulation of Conditioned Avoidance Behavior in Rats Eur. J. Pharmacol. 2014, 727, 130-139 10.1016/j.ejphar.2014.01.044
275. Andrés, J. I.; Alcázar, J.; Cid, J. M.; De Angelis, M.; Iturrino, L.; Langlois, X.; Lavreysen, H.; Trabanco, A. A.; Celen, S.; Bormans, G. Synthesis, Evaluation, and Radiolabeling of New Potent Positive Allosteric Modulators of the Metabotropic Glutamate Receptor 2 as Potential Tracers for Positron Emission Tomography Imaging J. Med. Chem. 2012, 55, 8685-8699 10.1021/jm300912k
276. Cid, J. M.; Duvey, G.; Tresadern, G.; Nhem, V.; Furnari, R.; Cluzeau, P.; Vega, J. A.; de Lucas, A. I.; Matesanz, E.; Alonso, J. M. et al. Discovery of 1,4-Disubstituted 3-Cyano-2-pyridones: A New Class of Positive Allosteric Modulators of the Metabotropic Glutamate 2 Receptor J. Med. Chem. 2012, 55, 2388-2405 10.1021/jm2016864
277. Addex Reports Top-line Data from a Successful Phase 2a Clinical Study with ADX71149 in Schizophrenia Patients (Press Release). Addex Pharmaceuticals, Nov 5, 2012; available at http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-a-successful-phase-2a-clinical-study-with-adx71149-in-schizophrenia/ (accessed Sep 1, 2015).
278. Cid, J. M.; Tresadern, G.; Duvey, G.; Lütjens, R.; Finn, T.; Rocher, J. P.; Poli, S.; Vega, J. A.; de Lucas, A. I.; Matesanz, E. et al. Discovery of 1-Butyl-3-chloro-4-(4-phenyl-1-piperidinyl)-(1H)-pyridone (JNJ-40411813): A Novel Positive Allosteric Modulator of the Metabotropic Glutamate 2 Receptor J. Med. Chem. 2014, 57, 6495-6512 10.1021/jm500496m
279. Lavreysen, H.; Ahnaou, A.; Drinkenburg, W.; Langlois, X.; Mackie, C.; Pype, S.; Lütjens, R.; LePoul, E.; Trabanco, A. A.; Cid Nuñez, J. M. Pharmacological and Pharmacokinetic Properties of JNJ-40411813, a Positive Allosteric Modulator of the mGlu2 Receptor Pharmacol. Res. Perspect. 2015, 3 (1) e00096 10.1002/prp2.96
280. Lavreysen, H.; Langlois, X.; Ver Donck, L.; Cid Nuñez, J. M.; Pype, S.; Lütjens, R.; Megens, A. Preclinical Evaluation of the Antipsychotic Potential of the mGlu2-Positive Allosteric Modulator JNJ-40411813 Pharmacol. Res. Perspect. 2015, 3, e00097 10.1002/prp2.97
281. Addex Reports Top-line Data from ADX71149 Phase 2a Study in Patients with Major Depressive Disorder (MDD) with Significant Anxiety Symptoms (Press Release). Addex Pharmaceuticals, Feb 7, 2014; available at http://www.addextherapeutics.com/investors/press-releases/news-details/article/addex-reports-top-line-data-from-adx71149-phase-2a-study-in-patients-with-major-depressive-disorder/ (accessed Sep 2, 2015).
282. Cook, D.; Brown, D.; Alexander, R.; March, R.; Morgan, P.; Satterthwaite, G.; Pangalos, M. N. Lessons Learned from the Fate of AstraZeneca's Drug Pipeline: A Five Dimensional Framework Nat. Rev. Drug Discovery 2014, 13, 419-431 10.1038/nrd4309
283. The structure of AZD8529 can be found at PubChem (CID 25125217): http://pubchem.ncbi.nlm.nih.gov/compound/25125217 (accessed Sep 2, 2015).
284. Justinova, Z.; Panlilio, L. V.; Secci, M. E.; Redhi, G. H.; Schindler, C. W.; Cross, A. J.; Mrzljak, L.; Medd, A.; Shaham, Y.; Goldberg, S. R. The Novel Metabotropic Glutamate Receptor 2 Positive Allosteric Modulator, AZD8529, Decreases Nicotine Self-Administration and Relapse in Squirrel Monkeys Biol. Psychiatry 2015, 78, 452-462 10.1016/j.biopsych.2015.01.014
285. The study of AZD8529 for Smoking Cessation in Female Smokers. https://www.clinicaltrials.gov/ct2/show/NCT02401022 (accessed Sep 2, 2015).
286. Ball, M.; Boyd, A.; Churchill, G.; Cuthbert, M.; Drew, M.; Fielding, M.; Ford, G.; Frodsham, L.; Golden, M.; Leslie, K. et al. Isoindolone Formation via Intramolecular Diels-Alder Reaction Org. Process Res. Dev. 2012, 16, 741-747 10.1021/op300002f
287. Campo, B.; Kalinichev, M.; Lambeng, N.; Yacoubi, M. E.; Royer-Urios, I.; Schneider, M.; Legrand, C.; Parron, D.; Girard, F.; Bessif, A. et al. Characterization of an mGluR2/3 Negative Allosteric Modulator in Rodent Models of Depression J. Neurogenet. 2011, 25, 152-166 10.3109/01677063.2011.627485
288. Pritchett, D.; Jagannath, A.; Brown, L. A.; Tam, S. K. E.; Hasan, S.; Gatti, S.; Harrison, P. J.; Bannerman, D. M.; Foster, R. G.; Peirson, S. N. Deletion of Metabotropic Glutamate Receptors 2 and 3 (mGlu2 & mGlu3) in Mice Disrupts Sleep and Wheel-Running Activity, and Increases the Sensitivity of the Circadian System to Light PLoS One 2015, 10, e0125523 10.1371/journal.pone.0125523
289. Woltering, T. J.; Wichmann, J.; Goetschi, E.; Knoflach, F.; Ballard, T. M.; Huwyler, J.; Gatti, S. Synthesis and Characterization of 1,3-d = Dihydro-benzo[b][1,4]diazepin-2-one Derivatives: Part 4. In Vivo Active Potent and Selective Non-Competitive Metabotropic Glutamate Receptor 2/3 Antagonists Bioorg. Med. Chem. Lett. 2010, 20, 6969-6974 10.1016/j.bmcl.2010.09.125
290. Yacoubi, M. E.; Vaugeois, J.-M.; Kalinichev, M.; Célanire, S.; Parron, D.; Le Poul, E.; Campo, B. Effects of a mGluR2/3 Negative Allosteric Modulator and a Reference mGluR2/3 Orthosteric Antagonist in a Genetic Mouse Model of Depression. In Behavioral Studies of Mood Disorders, Proceedings of the 40th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov 13-17, 2010; Society for Neuroscience: Washington, DC, 2010; 886.14/VV7.
291. Goeldner, C.; Ballard, T. M.; Knoflach, F.; Wichmann, J.; Gatti, S.; Umbricht, D. Cognitive Impairment in Major Depression and the mGlu2 Receptor as a Therapeutic Target Neuropharmacology 2013, 64, 337-346 10.1016/j.neuropharm.2012.08.001
292. Kalinichev, M.; Campo, B.; Lambeng, N.; Célanire, S.; Schneider, M.; Bessif, A.; Royer-Urios, I.; Parron, D.; Legrand, C.; Mahious, N. et al., An mGluR2/3 Negative Allosteric Modulator Improves Recognition Memory Assessed by Natural Forgetting in the Novel Object Recognition Test in Rats. In Memory Consolidation and Reconsolidation: Molecular Mechanisms II, Proceedings of the 40th Annual Meeting of the Society for Neuroscience, San Diego, CA, Nov 13-17, 2010; Society for Neuroscience: Washington, DC, 2010; 406.9/MMM57.
293. For the structure of decoglurant, see: International Nonproprietary Names. In WHO Drug Information; World Health Organization: Geneva, Switzerland, 2013; Vol. 27, No. 2, p 150.
294. ARTDeCo Study: A Study of RO4995819 in Patients with Major Depressive Disorder and Inadequate Response to Ongoing Antidepressant Treatment. https://www.clinicaltrials.gov/ct2/show/NCT01457677 (accessed Sep 2, 2015).
295. 5 Negative Allosteric Modulators: A Patent Review Expert Opin. Ther. Pat. 2013, 23, 393-408 10.1517/13543776.2013.760544
296. Mayer, S.; Cardona, L.; Catelain, T.; Courivaurd, F.; Hommet, G.; Lotz, N.; Manteau, B.; Mikidadi, S.; Steinberg, E.; Deshons, L. et al., Synthesis and Characterization of Pyrazolo[1,5-a]quinazolin-5-one Derivatives: Potent Non-Competitive mGluR2 NAMs. From Hit to in Vivo Procognition Proof of Concept. Presented at Drug Development, 8th International Meeting on Metabotropic Glutamate Receptors, Taormina, Sicily, Italy, Sep 28-Oct 3, 2014; Poster 19.
297. Schann, S.; Manteau, B.; Franchet, C.; Frauli, M.; Mayer, S. Molecular Switch Strategy Delivers Distinct Group II mGluR Allosteric Modulator Families. Presented at the 246th ACS National Meeting and Exposition, Indianapolis, IN, Sep 8-12, 2013; Article No. 268.
298. 3 NAMs Bioorg. Med. Chem. Lett. 2014, 24, 2693-2698 10.1016/j.bmcl.2014.04.051
299. Walker, A. G.; Wenthur, C. J.; Xiang, Z.; Rook, J. M.; Emmitte, K. A.; Niswender, C. M.; Lindsley, C. W.; Conn, P. J. Metabotropic Glutamate Receptor 3 Activation is Required for Long-Term Depression in Medial Prefrontal Cortex and Fear Extinction Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 1196-1201 10.1073/pnas.1416196112
300. Engers, J. L.; Rodriguez, A. L.; Konkol, L. C.; Morrison, R. D.; Thompson, A. D.; Byers, F. W.; Blobaum, A. L.; Chang, S.; Venable, D. F.; Loch, M. T. et al. Discovery of VU0650786: A Selective and CNS Penetrant Negative Allosteric Modulator of Metabotropic Glutamate Receptor Subtype 3 with Antidepressant and Anxiolytic Activity in Rodents J. Med. Chem. 2015, 58, 7485-7500 10.1021/acs.jmedchem.5b01005
301. Zhang, L.; Balan, G.; Barreiro, G.; Boscoe, B. P.; Chenard, L. K.; Cianfrogna, J.; Claffey, M. M.; Chen, L.; Coffman, K. J.; Drozda, S. E. et al. Discovery and Preclinical Characterization of 1-Methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): A Highly Potent, Selective, and Efficacious Metabotropic Glutamate Receptor 5 (mGluR5) Negative Allosteric Modulator J. Med. Chem. 2014, 57, 861-877 10.1021/jm401622k
302. Zhuo, X.; Huang, X. S.; Degnan, A. P.; Snyder, L. B.; Yang, F.; Huang, H.; Shu, Y.-Z.; Johnson, B. M. Identification of Glutathione Conjugates of Acetylene-Containing Positive Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5 Drug Metab. Dispos. 2015, 43, 578-589 10.1124/dmd.114.061879
303. Bungard, C. J.; Converso, A.; De Leon, P.; Hanney, B.; Hartingh, T. J.; Manikowski, J. J.; Manley, P. J.; Meissner, R.; Meng, Z.; Perkins, J. J.; Rudd, M. T.; Shu, Y. (Merck Sharp & Dohme Corp.). Quinoline Carboxamide and Quinoline Carbonitrile Derivatives as mGluR2-Negative Allosteric Modulators, Compositions, and Their Use. PCT International Patent Application WO 2013/066736 A1, May 10, 2013.
304. Ma, L.; Seager, M.; Wittmann, M.; Jacobson, M.; Bickel, N.; Burno, M.; Jones, K.; Graufelds, V. K.; Xu, G.; Pearson, M.; McCampbell, A. et al. Selective Activation of the M1 Muscarinic Acetylcholine Receptor Achieved by Allosteric Potentiation Proc. Natl. Acad. Sci. U. S. A. 2009, 106, 15950-15955 10.1073/pnas.0900903106
305. Felts, A. S.; Rodriguez, A. L.; Smith, K. A.; Engers, J. L.; Morrison, R. D.; Byers, F. W.; Blobaum, A. L.; Locuson, C. W.; Chang, S.; Venable, D. F. et al. Design of 4-Oxo-1-aryl-1,4-dihydroquinoline-3-carboxamides as Selective Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 2 J. Med. Chem. 2015, 58, 9027-9040 10.1021/acs.jmedchem.5b01371
306. 4 Receptor Provides Functional Neuroprotection in the 6-Hydroxydopamine Rat Model of Parkinson's Disease Br. J. Pharmacol. 2012, 166, 2317-2330 10.1111/j.1476-5381.2012.01943.x
307. 4) with CNS Exposure in Rats J. Med. Chem. 2011, 54, 1106-1110 10.1021/jm101271s
308. 4 Receptor Neuropharmacology 2013, 66, 225-235 10.1016/j.neuropharm.2012.05.001
309. Kalinichev, M.; Le Poul, E.; Bolea, C.; Girard, F.; Campo, B.; Fonsi, M.; Royer-Urios, I.; Browne, S. E.; Uslaner, J. M.; Davis, M. J. et al. Characterization of the Novel Positive Allosteric Modulator of the Metabotropic Glutamate Receptor 4 ADX88178 in Rodent Models of Neuropsychiatric Disorders J. Pharmacol. Exp. Ther. 2014, 350, 495-505 10.1124/jpet.114.214437
310. Sławińska, A.; Wierońska, J. M.; Stachowicz, K.; Marciniak, M.; Łasoń-Tyburkiewicz, M.; Gruca, P.; Papp, M.; Kusek, M.; Tokarski, K.; Doller, D. et al. The Antipsychotic-Like Effects of Positive Allosteric Modulators of Metabotropic Glutamate mGlu4 Receptors in Rodents Br. J. Pharmacol. 2013, 169, 1824 10.1111/bph.12254
311. 5 NAMs, PAMs, and Partial Antagonists Bioorg. Med. Chem. Lett. 2011, 21, 2711-2714 10.1016/j.bmcl.2010.11.119
312. 5 Negative Allosteric Modulators Attenuate Cocaine Self-Administration, Demonstrate Antidepressant- and Anxiolytic-Like Activity and Lack Psychotomimetic Effects' Neuropsychopharmacology 2015, 102, 244-253 10.1038/npp.2015.265
313. Nickols, H. H.; Yuh, J. P.; Gregory, K.; Morrison, R.; Bates, B. S.; Stauffer, S.; Emmitte, K.; Bubser, M.; Peng, W.; Nedelcovych, M. T. et al. VU0477573: Partial Negative Allosteric Modulator of the Subtype 5 Metabotropic Glutamate Receptor with High in Vivo Efficacy J. Pharmacol. Exp. Ther. 2016, 356, 123-136 10.1124/jpet.115.226597
314. Ellard, J. M.; Madin, A.; Philps, O.; Hopkin, M.; Henderson, S.; Birch, L.; O'Connor, D.; Arai, T.; Takase, K.; Morgan, L. et al. Identification and Optimisation of a Series of Tetrahydrobenzotriazoles as Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulators that Improve Performance in a Preclinical Model of Cognition Bioorg. Med. Chem. Lett. 2015, 25, 5792-5796 10.1016/j.bmcl.2015.10.050
315. Hamilton, S. P. A New Lead From Genetic Studies in Depressed Siblings: Assessing Studies of Chromosome 3 Am. J. Psychiatry 2011, 168, 783-789 10.1176/appi.ajp.2011.11060835
316. Breen, G.; Webb, B. T.; Butler, A. W.; van den Oord, E. J.; Tozzi, F.; Craddock, N.; Gill, M.; Korszun, A.; Maier, W.; Middleton, L. et al. A Genome-Wide Significant Linkage for Severe Depression on Chromosome 3: The Depression Network Study Am. J. Psychiatry 2011, 168, 840-847 10.1176/appi.ajp.2011.10091342
317. Ganda, C.; Schwab, S. G.; Amir, N.; Heriani, H.; Irmansyah, I.; Kusumawardhani, A.; Nasrun, M.; Widyawati, I.; Maier, W.; Wildenauer, D. B. A Family-Based Association Study of DNA Sequence Variants in GRM7 with Schizophrenia in an Indonesian Population Int. J. Neuropsychopharmacol. 2009, 12, 1283-1289 10.1017/S1461145709990356
318. Mick, E.; Neale, B.; Middleton, F. A.; McGough, J. J.; Faraone, S. V. Genome-Wide Association Study of Response to Methylphenidate in 187 Children with Attention-Deficit/Hyperactivity Disorder Am. J. Med. Genet., Part B 2008, 147B, 1412 10.1002/ajmg.b.30865
319. Yang, Y.; Pan, C. Role of Metabotropic Glutamate Receptor 7 in Autism Spectrum Disorders: A Pilot Study Life Sci. 2013, 92, 149-153 10.1016/j.lfs.2012.11.010
320. Park, S.; Kim, B. N.; Cho, S. C.; Kim, J. W.; Kim, J. I.; Shin, M. S.; Yoo, H. J.; Han, D. H.; Cheong, J. H. The Metabotropic Glutamate Receptor Subtype 7 rs3792452 Polymorphism is Associated with the Response to Methylphenidate in Children with Attention-Deficit/Hyperactivity Disorder J. Child Adolesc. Psychopharmacol. 2014, 24, 223-227 10.1089/cap.2013.0079
321. Horikoshi, M.; Yaghootkar, H.; Mook-Kanamori, D. O.; Sovio, U.; Taal, H. R.; Hennig, B. J.; Bradfield, J. P.; St. Pourcain, B.; Evans, D. M.; Charoen, P. et al. New Loci Associated with Birth Weight Identify Genetic Links between Intrauterine Growth and Adult Height and Metabolism Nat. Genet. 2013, 45, 76-82 10.1038/ng.2477
322. Ohtsuki, T.; Koga, M.; Ishiguro, H.; Horiuchi, Y.; Arai, M.; Niizato, K.; Itokawa, M.; Inada, T.; Iwata, N.; Iritani, S. et al. A Polymorphism of the Metabotropic Glutamate Receptor mGluR7 (GRM7) Gene is Associated with Schizophrenia Schizophr. Res. 2008, 101, 9-16 10.1016/j.schres.2008.01.027
323. Shibata, H.; Tani, A.; Chikuhara, T.; Kikuta, R.; Sakai, M.; Ninomiya, H.; Tashiro, N.; Iwata, N.; Ozaki, N.; Fukumaki, Y. Association Study of Polymorphisms in the Group III Metabotropic Glutamate Receptor Genes, GRM4 and GRM7, with Schizophrenia Psychiatry Res. 2009, 167, 88-96 10.1016/j.psychres.2007.12.002
324. Saus, E.; Brunet, A.; Armengol, L.; Alonso, P.; Crespo, J. M.; Fernandez-Aranda, F.; Guitart, M.; Martin-Santos, R.; Menchon, J. M.; Navines, R. et al. Comprehensive Copy Number Variant (CNV) Analysis of Neuronal Pathways Genes in Psychiatric Disorders Identifies Rare Variants Within Patients J. Psychiatr. Res. 2010, 44, 971-978 10.1016/j.jpsychires.2010.03.007
325. Jajodia, A.; Kaur, H.; Kumari, K.; Gupta, M.; Baghel, R.; Srivastava, A.; Sood, M.; Chadda, R. K.; Jain, S.; Kukreti, R. Evidence for Schizophrenia Susceptibility Alleles in the Indian Population: An Association of Neurodevelopmental Genes in Case-Control and Familial Samples Schizophr. Res. 2015, 162, 112-117 10.1016/j.schres.2014.12.031
326. Kandaswamy, R.; McQuillin, A.; Curtis, D.; Gurling, H. Allelic Association, DNA Resequencing and Copy Number Variation at the Metabotropic Glutamate Receptor GRM7 Gene Locus in Bipolar Disorder Am. J. Med. Genet., Part B 2014, 165, 365-372 10.1002/ajmg.b.32239
327. Alliey-Rodriguez, N.; Zhang, D.; Badner, J. A.; Lahey, B. B.; Zhang, X.; Dinwiddie, S.; Romanos, B.; Plenys, N.; Liu, C.; Gershon, E. S. Genome-Wide Association Study of Personality Traits in Bipolar Patients Psychiatr. Genet. 2011, 21, 190-194 10.1097/YPG.0b013e3283457a31
328. Nho, K.; Ramanan, V. K.; Horgusluoglu, E.; Kim, S.; Inlow, M. H.; Risacher, S. L.; McDonald, B. C.; Farlow, M. R.; Foroud, T. M. et al. Comprehensive Gene- and Pathway-Based Analysis of Depressive Symptoms in Older Adults J. Alzheimers Dis. 2015, 45, 1197-1206
329. Haenisch, S.; Zhao, Y.; Chhibber, A.; Kaiboriboon, K.; Do, L. V.; Vogelgesang, S.; Barbaro, N. M.; Alldredge, B. K.; Lowenstein, D. H.; Cascorbi, I.; Kroetz, D. L. SOX11 Identified by Target Gene Evaluation of miRNAs Differentially Expressed in Focal and Non-Focal Brain Tissue of Therapy-Resistant Epilepsy Patients Neurobiol. Dis. 2015, 77, 127-140 10.1016/j.nbd.2015.02.025
330. Mitsukawa, K.; Yamamoto, R.; Ofner, S.; Nozulak, J.; Pescott, O.; Lukic, S.; Stoehr, N.; Mombereau, C.; Kuhn, R.; McAllister, K. H. et al. A Selective Metabotropic Glutamate Receptor 7 Agonist: Activation of Receptor Signaling via an Allosteric Site Modulates Stress Parameters in Vivo Proc. Natl. Acad. Sci. U. S. A. 2005, 102, 18712-18717 10.1073/pnas.0508063102
331. Sukoff Rizzo, S. J.; Leonard, S. K.; Gilbert, A.; Dollings, P.; Smith, D. L.; Zhang, M. Y.; Di, L.; Platt, B. J.; Neal, S.; Dwyer, J. M. et al. The Metabotropic Glutamate Receptor 7 Allosteric Modulator AMN082: A Monoaminergic Agent in Disguise? J. Pharmacol. Exp. Ther. 2011, 338, 345-352 10.1124/jpet.110.177378
332. Jalan-Sakrikar, N.; Field, J. R.; Klar, R.; Mattmann, M. E.; Gregory, K. J.; Zamorano, R.; Engers, D. W.; Bollinger, S. R.; Weaver, C. D.; Days, E. L. et al. Identification of Positive Allosteric Modulators VU0155094 (ML397) and VU0422288 (ML396) Reveals New Insights Into the Biology of Metabotropic Glutamate Receptor 7 ACS Chem. Neurosci. 2014, 5, 1221-1237 10.1021/cn500153z
333. Ayala, J. E.; Niswender, C. M.; Luo, Q.; Banko, J. L.; Conn, P. J. Group III mGluR Regulation of Synaptic Transmission at the SC-CA1 Synapse is Developmentally Regulated Neuropharmacology 2008, 54, 804 10.1016/j.neuropharm.2007.12.009
334. Baskys, A.; Malenka, R. C. Agonists at Metabotropic Glutamate Receptors Presynaptically Inhibit EPSCs in Neonatal Rat Hippocampus J. Physiol. 1991, 444, 687-701 10.1113/jphysiol.1991.sp018901
335. Klar, R.; Walker, A. G.; Ghose, D.; Grueter, B. A.; Engers, D. W.; Hopkins, C. R.; Lindsley, C. W.; Xiang, Z.; Conn, P. J.; Niswender, C. M. Activation of Metabotropic Glutamate Receptor 7 is Required for Induction of Long-Term Potentiation at SC-CA1 Synapses in the hippocampus J. Neurosci. 2015, 35, 7600-7615 10.1523/JNEUROSCI.4543-14.2015
336. Gee, C. E.; Peterlik, D.; Neuhäuser, C.; Bouhelal, R.; Kaupmann, K.; Laue, G.; Uschold-Schmidt, N.; Feuerbach, D.; Zimmermann, K.; Ofner, S. et al. Blocking Metabotropic Glutamate Receptor Subtype 7 (mGlu7) via the Venus Flytrap Domain (VFTD) Inhibits Amygdala Plasticity, Stress, and Anxiety-Related Behavior J. Biol. Chem. 2014, 289, 10975-10987 10.1074/jbc.M113.542654
337. Suzuki, G.; Tsukamoto, N.; Fushiki, H.; Kawagishi, A.; Nakamura, M.; Kurihara, H.; Mitsuya, M.; Ohkubo, M.; Ohta, H. In Vitro Pharmacological Characterization of Novel Isoxazolopyridone Derivatives as Allosteric Metabotropic Glutamate Receptor 7 Antagonists J. Pharmacol. Exp. Ther. 2007, 323, 147-156 10.1124/jpet.107.124701
338. Nakamura, M.; Kurihara, H.; Suzuki, G.; Mitsuya, M.; Ohkubo, M.; Ohta, H. Isoxazolopyridone Derivatives as Allosteric Metabotropic Glutamate Receptor 7 Antagonists Bioorg. Med. Chem. Lett. 2010, 20, 726-729 10.1016/j.bmcl.2009.11.070
339. Yamasaki, T.; Kumata, K.; Yui, J.; Fujinaga, M.; Furutsuka, K.; Hatori, A.; Xie, L.; Ogawa, M.; Nengaki, N. et al. Synthesis and Evaluation of [11C]MMPIP as a Potential Radioligand for Imaging of Metabotropic Glutamate 7 Receptor in the Brain EJNMMI Res. 2013, 3, 54 10.1186/2191-219X-3-54
340. Niswender, C. M.; Johnson, K. A.; Miller, N. R.; Ayala, J. E.; Luo, Q.; Williams, R.; Saleh, S.; Orton, D.; Weaver, C. D.; Conn, P. J. Context-Dependent Pharmacology Exhibited by Negative Allosteric Modulators of Metabotropic Glutamate Receptor 7 Mol. Pharmacol. 2010, 77, 459-468 10.1124/mol.109.058768
341. Kalinichev, M.; Rouillier, M.; Girard, F.; Royer-Urios, I.; Bournique, B.; Finn, T.; Charvin, D.; Campo, B.; Le Poul, E.; Mutel, V. et al. ADX71743, a Potent and Selective Negative Allosteric Modulator of Metabotropic Glutamate Receptor 7: In Vitro and in Vivo Characterization J. Pharmacol. Exp. Ther. 2013, 344, 624-636 10.1124/jpet.112.200915
342. Pert, C. B.; Snyder, S. H. Properties of Opiate Receptor Bindign in Rat Brain Proc. Natl. Acad. Sci. U. S. A. 1973, 70, 2243-2247 10.1073/pnas.70.8.2243
343. Fraser, C. M.; Wang, C.-D.; Robinson, D. A.; Gocayne, J. D.; Venter, J. C. Site-Directed Mutagenesis of M1 Muscarinic Acetylcholine Receptors: Conserved Aspartic Acids Play Important Roles in Receptor Function Mol. Pharmacol. 1989, 36, 840-847
344. B Receptors ACS Med. Chem. Lett. 2014, 5, 742-747 10.1021/ml500162z
345. Tobo, A.; Tobo, M.; Nakakura, T.; Ebara, M.; Tomura, H.; Mogi, C.; Im, D.-S.; Murata, N.; Kuwabara, A.; Ito, S. et al. Characterization of Imidazopyridine Compounds as Negative Allosteric Modulators of Proton-Sensign GPR4 in Extracellular Acidification-Induced Responses PLoS One 2015, 10, e0129334 10.1371/journal.pone.0129334